Skip to main content
PLOS Genetics logoLink to PLOS Genetics
. 2021 Nov 8;17(11):e1009873. doi: 10.1371/journal.pgen.1009873

The FASTK family proteins fine-tune mitochondrial RNA processing

Akira Ohkubo 1, Lindsey Van Haute 2, Danielle L Rudler 3,4,5, Maike Stentenbach 3,4,5, Florian A Steiner 6, Oliver Rackham 3,4,7,8,9, Michal Minczuk 2, Aleksandra Filipovska 3,4,5,9,10,‡,*, Jean-Claude Martinou 1,‡,*
Editor: Christoph Freyer11
PMCID: PMC8601606  PMID: 34748562

Abstract

Transcription of the human mitochondrial genome and correct processing of the two long polycistronic transcripts are crucial for oxidative phosphorylation. According to the tRNA punctuation model, nucleolytic processing of these large precursor transcripts occurs mainly through the excision of the tRNAs that flank most rRNAs and mRNAs. However, some mRNAs are not punctuated by tRNAs, and it remains largely unknown how these non-canonical junctions are resolved. The FASTK family proteins are emerging as key players in non-canonical RNA processing. Here, we have generated human cell lines carrying single or combined knockouts of several FASTK family members to investigate their roles in non-canonical RNA processing. The most striking phenotypes were obtained with loss of FASTKD4 and FASTKD5 and with their combined double knockout. Comprehensive mitochondrial transcriptome analyses of these cell lines revealed a defect in processing at several canonical and non-canonical RNA junctions, accompanied by an increase in specific antisense transcripts. Loss of FASTKD5 led to the most severe phenotype with marked defects in mitochondrial translation of key components of the electron transport chain complexes and in oxidative phosphorylation. We reveal that the FASTK protein family members are crucial regulators of non-canonical junction and non-coding mitochondrial RNA processing.

Author summary

As a legacy of their bacterial origin, mitochondria have retained their own genome with a unique gene expression system. All mitochondrially encoded proteins are essential components of the respiratory chain. Therefore, the mitochondrial gene expression is crucial for their iconic role as the ‘powerhouse of the cell’–ATP synthesis through oxidative phosphorylation. Consistently, defects in enzymes involved in this gene expression system are a common source of incurable inherited metabolic disorders, called mitochondrial diseases. The human mitochondrial transcription generates long polycistronic transcripts that carry information for multiple genes, so that the expression level of each gene is mainly regulated through post-transcriptional events. The polycistronic transcript first undergoes RNA processing, where individual mRNA, rRNA, and tRNA are cleaved off. However, its entire molecular mechanism remains unclear, and in particular, ‘non-canonical’ RNA processing has been poorly understood. To address this question, we studied the FASTK family proteins, emerging key mitochondrial post-transcriptional regulators. We generated different human cell lines carrying single or combined disruption of FASTKD3, FASTKD4, and FASTKD5 genes, and analyzed them using biochemical and genetic approaches. We show that the FASTK family members fine-tune the processing of both ‘canonical’ and ‘non-canonical’ mitochondrial RNA junctions.

Introduction

The circular 16.5 kbp human mitochondrial DNA (mtDNA) encodes 37 genes including two rRNAs, 22 tRNAs, and 13 ORFs, all of which are essential for oxidative phosphorylation (OXPHOS) [1]. Mitochondrial transcription initiates at two distinct divergent promoters, one on each strand, leading to two almost genome-length polycistronic transcripts: the primary transcript generated from the heavy strand promoter (HSP) includes 8 monocistronic mRNAs, two bicistronic mRNAs (ND4L/4 and ATP8/6), 14 tRNAs, and two rRNAs, while the complementary primary transcript derived from the light strand promoter (LSP) encodes only one mRNA (ND6), 8 tRNAs, and long stretches of non-coding sequences [2,3]. As a consequence of the polycistronic organization of the primary transcripts, the expression level of each individual gene is mainly controlled through post-transcriptional events, including stabilization, processing and modification [46]. Most mRNAs and rRNAs within the polycistronic transcripts are flanked by tRNAs, and cleavage at the tRNA junctions by RNase P (MRPP1-3) and RNase Z (ELAC2) allows excision of the individual transcripts [713]. This is referred to as the ‘tRNA punctuation model’ [14,15], and the flanking tRNAs are named canonical processing junctions. However, this model does not explain the processing of mRNAs that lack flanking tRNAs. In human mitochondria, junctions not flanked by tRNA, here named non-canonical junctions, are found at the 3′ UTR of ND6, 5′ UTR of CO1, between ND5 and CYTB, and between ATP8/6 and CO3 mRNAs. The machinery responsible for processing these non-canonical junctions is currently unknown. Recent work has identified several candidates involved in the process, including the Fas-activated serine/threonine kinase (FASTK) family proteins [11,1619].

The FASTK family includes six RNA binding proteins (RBPs), FASTK and FASTKD1-5 [2023], all of which are localized in the mitochondrial matrix (Fig 1A) [16,1820,2427]. The available evidence to date suggests that the FASTK family proteins are broadly involved in post-transcriptional regulation, ranging from RNA maturation to translation, although the precise mode of action of different members of the family remains to be elucidated [20].

Fig 1. Generation of HAP1 cell lines carrying single or combined knockouts of FASTK family members.

Fig 1

(A) Overview of the FASTK protein family and their proposed roles in mitochondrial post-transcriptional regulation. All proteins share a conserved C-terminal domain architecture of FAST_1, FAST_2, and the RAP domains. An internal translation start site exposes a mitochondrial targeting sequence (MTS) leading to expression of the mitochondrial FASTK (mtFASTK). (B) Expression levels of FASTK family proteins and mtRBPs involved in the post-transcriptional regulation in WT (control) and FASTKDs-KO HAP1 cells were measured by immunoblotting. γ-tubulin was used as a loading control for whole cell lysates. mtHSP70 and VDAC1 were used as mitochondrial loading controls. A representative result from two independent experiments is shown.

FASTKD2 was described as part of a protein complex together with RPUSD3, RPUSD4, NGRN, WBSCR16 and PTCD1, involved in pseudouridylation of the 16S rRNA [19,2830]. Mutations in the FASTKD2 gene have been identified in patients with a MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke)-like syndrome [3134]. All other members of the FASTK family have been found to alter the expression levels of various mitochondrial mRNAs with some degree of specificity. While they regulate the abundance of specific mRNAs (Fig 1A) [16,18,19,24,26,27], others are also involved in the non-canonical mitochondrial RNA (mtRNA) processing events: mitochondrial FASTK (mtFASTK) and FASTKD4, for example, are specifically involved in the processing of pre-ND6 and ND5-CYTB transcripts, respectively [16,18]. In contrast, FASTKD5 is required for the processing of all the non-canonical junctions with the exception of the 3′ UTR of ND6 [19].

Despite their functional diversity, the FASTK family proteins share three putative RNA binding domains: FAST_1, FAST_2, and the RAP domain (Fig 1A) [22]. We and others have reported that the RAP domain seems structurally related to PD-(D/E)-XK nuclease superfamily [18,22,35], suggesting that this domain in the FASTK proteins may have endonuclease activity. Furthermore, RAP domain-containing proteins have been found to participate in nuclear and chloroplast RNA processing or splicing [3639]. For instance, in C. reinhardtii, the chloroplastic RAP-domain-containing Raa3 protein participates in the trans-splicing of psaA mRNA that encodes a protein involved in photosynthesis [40]. Importantly, during trans-splicing of the psaA mRNA, Raa3 forms a complex with the FAST_1 domain-containing protein, Raa1 [41], supporting the hypothesis that these domains in the FASTK family members could be directly involved in mtRNA processing [18].

Here, we have investigated the role of different FASTK family proteins in mtRNA processing. We generated human cell lines with single or combined disruption of FASTKD3, FASTKD4, and FASTKD5. Transcriptomic analyses of these knockout cells demonstrated defective processing of several canonical and non-canonical junctions, accompanied by specific increases in particular antisense transcripts. Our results support the hypothesis that the FASTK protein family members are critical regulators of mitochondrial RNA processing.

Results

The FASTK family proteins specifically regulate the levels of sense and antisense transcripts and non-canonical mtRNA processing

To obtain greater insight into the role of FASTK family members in mitochondrial post-transcriptional regulation, we generated human cell lines in which either a single member of the family or a combination of members were knocked out. Knockout (KO) cells were generated in the HAP1 haploid cell line using CRISPR/Cas9 genome editing, and the efficiency of each KO was assessed by immunoblotting (Fig 1B), Sanger sequencing (S1 Fig), and RNA sequencing (RNA-seq) (S2 Fig). We generated single KO cell lines for FASTKD3 (FASTKD3-sKO), FASTKD4 (FASTKD4-sKO) and FASTKD5 (FASTKD5-sKO), and two double KO cell lines (FASTKD3&4-dKO and FASTKD4&5-dKO) (Figs 1B and S1). It should be noted that subsequent analysis of the cell line in which FASTKD3 and FASTKD4 genes were deleted also carried a mutation in one of the FASTKD5 alleles. However, this did not result in a significantly decreased expression of FASTKD5 protein (Fig 1B), and we therefore considered this cell line as a FASTKD3&4-dKO.

Importantly, we found that the HAP1 cell line expresses all members of the family except FASTKD2, which is absent both at the mRNA (S3B Fig) and protein levels (S3A Fig). The reason for this lack of FASTKD2 expression specifically in this cell line is currently unknown.

We then characterized these different KO cell lines by immunoblotting to investigate the expression of other FASTK family proteins and known mitochondrial RNA binding proteins (mtRBPs) involved in post-transcriptional regulation of mitochondrial gene expression (Fig 1B). FASTKD5 protein expression was decreased in FASTKD3-sKO cells and FASTKD3 protein level was downregulated in FASTKD5-sKO cells (Fig 1B), suggesting that the stability of these proteins may depend on their interaction, as has been shown for several other proteins, such as prohibitin 1 and 2 [42,43] and the mitochondrial pyruvate carrier subunits 1 and 2 [44], which are only stable as heterodimers. Furthermore, the absence of FASTKD5 resulted in a substantial decrease in the MRPP1, ELAC2, and RPUSD4 proteins and an increase in the SUV3 protein as compared to controls (Fig 1B).

In the light of these results, we analyzed the different KO cell lines for mtRNA expression. We carried out northern blotting to measure the steady-state levels of mitochondrial transcripts, including non-coding RNAs (ncRNAs), in control and the FASTKDs-KO cell lines (Figs 2 and S4). Of note, all the analyzed antisense or ncRNAs appeared as distinct bands with different lengths, indicating that they are processed in a specific manner before degradation. Furthermore, some ncRNAs were clearly processed into shorter ncRNAs, which we refer to as small non-coding RNAs (sncRNAs) (Figs 2A and S4).

Fig 2. Loss of FASTKD proteins alters the abundance of coding and non-coding RNAs and perturbs non-canonical RNA processing.

Fig 2

(A) The steady-state levels of rRNAs, mRNAs and ncRNAs in WT (control) and FASTKDs-KO HAP1 cells were measured by northern blotting. 5S and 7SL were used as loading controls. The equal amount of total cellular RNA was loaded on several separate gel. Each comparison (WT vs KO) shown is from the same gel. A lane of WT is exceptionally used for both the pair of FASTKD4-sKO and the pair of FASTKD3&4-dKO. A representative result from three independent experiments is shown. (B-E) Relative abundance of mature rRNAs, mRNAs, ncRNAs derived from either the heavy strand (B) or the light strand (C), non-canonical precursor RNAs (D), and sncRNAs (E). The data from each of the FASTKDs-KO HAP1 cell lines were quantified by comparison to WT HAP1 cells (control) (n = 3, except for Fig 2D with n = 2 or 3). RNA loading was normalized to the content of 7SL RNA. The dotted line shows the relative abundance of control (= 1). Results are mean±SEM, *P<0.05, **P 0.001 to 0.01, ***P <0.001 (two-tailed unpaired t-test).

In the FASTKD3-sKO cells, the level of ND2, ATP8/6, and ND3 mRNAs derived from the HSP were significantly increased compared to controls (Fig 2A and 2B), consistent with our previous study [27]. However, LSP-derived transcripts were not particularly affected in these cells (Fig 2C).

Loss of FASTKD4 caused the reduction of ATP8/6, CO3, ND3, ND5, and CYTB mRNAs as well as impaired ND5-CYTB RNA processing (Fig 2A, 2B and 2D), consistent with previous findings [18,26]. In contrast to these HSP-derived transcripts, several transcripts derived from LSP, ND6, ncATP8/6, and ncCO1, were accumulated in the absence of FASTKD4 (Fig 2C). All sncRNAs except sncCYTB were decreased in the FASTKD4-sKO cells (Fig 2E), which is in contrast to the accumulation of their cognate longer ncRNAs. This finding suggests that FASTKD4 could be involved in the downstream processing of sncRNAs, in particular, sncATP8/6 and sncCO1.

Loss of FASTKD5 resulted in a significant accumulation of ND1, ND2 and CO2 mRNAs and a decrease in CO1, ATP8/6, CO3, and ND5 mRNAs (Fig 2A and 2B). Furthermore, processing of pre-CO1, ATP8/6-CO3, and ND5-CYTB non-canonical precursor transcripts, was impaired, as previously reported [19], and this defect was particularly striking for pre-CO1 and ATP8/6-CO3 RNA processing, resulting in very low levels of mature mRNAs (Fig 2A and 2D). By comparison to FASTKD4-sKO cells, the processing defect of ND5-CYTB in the FASTKD5-sKO cells was subtle. This indicates that ND5-CYTB RNA processing is mainly regulated by FASTKD4. On the other hand, among the transcripts derived from LSP, only ncATP8/6 RNA dramatically accumulated when FASTKD5 was absent (Fig 2A and 2C). It is important to note that the sncATP8/6 RNA level was reduced in the FASTKD5-sKO cells, as it was in the FASTKD4-sKO cells. This finding suggests that FASTKD4 and FASTKD5 cooperate in the processing of sncATP8/6 RNA. It is noteworthy that the HSP-derived transcripts, ND2, CO2, and ND3 mRNAs, accumulated in either FASTKD3-sKO or FASTKD5-sKO cells (Fig 2B). However, the molecular phenotypes of the two cell lines showed some distinct changes. If, as proposed above, the stability of these two proteins was interdependent, one would expect similar phenotypes for both KO cells. The fact that there is residual FASTKD5 in FASTKD3-sKO and some FASTKD3 in FASTKD5-sKO cells may explain the observed differences between the two cell lines.

Next, we investigated mtRNA expression in the double KO cells. FASTKD3&4-dKO resulted in a decrease in ATP8/6, CO3, ND3, ND5, and CYTB mRNAs with impaired ND5-CYTB RNA processing (Fig 2A, 2B and 2D), which is similar to the phenotype of FASTDK4-sKO cells. Notably, the ND3 mRNA level, which is antagonistically regulated by FASTKD3 and FASTKD4, was decreased in the FASTKD3&4-dKO cells, as it was in the FASTKD4-sKO cells. Interestingly, LSP-derived transcripts were not significantly affected in the FASTKD3&4-dKO cells, in contrast to the single FASTKD4-sKO cells (Fig 2C). However, sncCO2 and sncCO1 RNA levels were most decreased in the dKO cells, similar to in the FASTKD4-sKO cells (Fig 2E), further supporting the essential role of FASTKD4 in the generation of sncCO1 RNA.

Double knockout of FASTKD4 and FASTKD5 caused a decrease in CO1, ATP8/6, CO3, ND3, ND5, and CYTB mRNAs with defective processing of pre-CO1, ATP8/6-CO3, and ND5-CYTB precursor RNAs (Fig 2A, 2B and 2D). This phenotype is therefore the result of the combined effects of the sKOs, which suggests that these two proteins may play overlapping or cooperative functions. This is particularly striking for the ND5-CYTB RNA processing, which was completely absent in the dKO cell line (Fig 2A). However, the ND1 and ND2 mRNA levels, which were increased in the FASTKD5-sKO cells, were comparable to the controls in the FASTKD4&5-dKO cells as well as in the FASTKD4-sKO cells (Fig 2B). ncND5 was the only LSP-derived transcript that accumulated significantly in the FASTKD4&5-dKO cells (Fig 2C). The FASTK4&5-dKO additionally resulted in a dramatic decrease in sncATP8/6, sncCO2, and sncCO1 RNAs (Fig 2E). In contrast to our findings in the FASTKD4-sKO cells, the FASTKD3&4-dKO and the FASTKD4&5-dKO cell lines only showed mild accumulation of ncRNAs, suggesting that the ncRNA levels could be compensated by other mtRBPs when multiple FASTKD proteins are lost.

We observed that the overall mitochondrial transcription level, as assessed by the level of 7S RNA, which is the most LSP-proximal transcript, appeared normal in all the KO cell lines (S3C Fig). Moreover, mtDNA abundance was also not altered in any of the KO cell lines (S3D Fig), consistent with the unchanged level of LSP transcription that forms a DNA replication primer (S3C Fig) [45]. In addition, we carried out SSBP1 and BrU staining to assess mitochondrial DNA replication and transcription respectively, and in both cases, we found similar levels of immunostaining in all the KO and control cells (S3E Fig). These findings are therefore entirely consistent with the hypothesis that the FASTK family proteins are involved in post-transcriptional regulation, and they fully support our conclusions from the northern blotting analyses (Fig 2) that the regulation of mtRNA abundance is a consequence of post-transcriptional events.

It is notable that the accumulation of ncRNAs in the different FASTKD-KO cells was often inversely correlated with the change in their complementary mRNAs (Fig 2B and 2C). For instance, the antisense transcript of ATP8/6 accumulated following the loss of either FASTKD4 or FASTKD5, whereas its complementary ATP8/6 mRNA was decreased in these sKO cells. This suggests the possibility that the FASTKD proteins could regulate the levels of specific mRNAs through the processing and degradation of their antisense ncRNAs. This process would probably involve recruitment of the mtRNA degradosome, and indeed, the pattern of ncRNAs in the FASTKD4-sKO cells is reminiscent of the phenotype of cells lacking PNPase, the catalytic enzyme of the mtRNA degradosome [46]. Furthermore, PNPase was recently found to prevent the accumulation of mitochondrial double-stranded RNA (dsRNA) [47], which may potentially inhibit mtRNA processing due to duplex formation. Mitochondrial dsRNA can be quantified using the anti-dsRNA J2 antibody [47,48]. However, we found that in the FASTKD4-sKO cells, the J2 immunostaining, as well as the quantification of mitochondrial dsRNA by dot blotting, did not change compared to controls (S3E and S3F Fig). Nonetheless, since the J2 antibody only recognizes dsRNA that is longer than 40 nucleotides, we cannot rule out that shorter dsRNA molecules might accumulate in FASTKD4-sKO cells.

Mitochondrial transcriptomics demonstrates the specific roles of the FASTKD proteins in stability and processing of both sense and antisense transcripts

In a complementary study, we carried out RNA-seq using the procedures we have reported previously [12,13,29] to analyze the effects of the different FASTKD gene KOs on the mitochondrial transcriptome. We first investigated the abundance of rRNAs and mRNAs in each of the FASTKDs-KO cell lines (Fig 3A). In most cases, the RNA-seq data confirmed the results of northern blotting, although some exceptions were noted: the RNA-seq data showed that loss of FASTKD4 additionally caused a reduction in ND1, ND2, ND4L/4 and ND6 mRNAs, and the FASTKD3&4-dKO caused a reduction in ND1, ND2, and ND6 mRNAs, while the FASTKD4&5-dKO resulted in an increase in the 16S rRNA, which was not observed in either sKO. These findings, together with the northern blot data (Fig 2), indicate that the loss of FASTKD4 and FASTKD5 have the most significant effects on the stability of specific mRNAs.

Fig 3. Mitochondrial transcriptome analysis of the FASTKDs-KO cells by RNA-seq.

Fig 3

(A) Relative abundance of read counts normalized to total reads for mitochondrial mRNAs were analyzed. Results are mean±SD *P<0.05, **P<0.01 (Wald test). (B-C) A complete map of mtRNA abundance and mean (log2 fold change [KOmean/Ctrlmean]) determined by RNA-seq coverage from control, FASTKD3-sKO, FASTKD4-sKO, FASTKD5-sKO, FASTKD3&4-dKO, and FASTKD4&5-dKO cells (n = 3). Increases in coding regions (B) and rRNA regions (C) are shown in red, and decreases in coding regions (B) and rRNA regions (C) are shown in blue. The range of the log2 fold changes are from -3 to 2.8.

We next analyzed the entire mitochondrial transcriptome for processing defects as a result of different FASTKD gene knockouts. The RNA-seq library construction approach enabled us to exclude mature tRNAs and retain unprocessed transcripts containing tRNAs that intersperse adjacent coding regions in the mitochondrial transcriptome. In the FASTKD3-sKO cells, there were no processing defects for any heavy strand-encoded RNAs indicating that this protein does not play a major role in mitochondrial RNA cleavage (Fig 3B). However, its loss resulted in specific increases in tRNAE- and tRNAQ-containing LSP-derived precursor RNAs. In the FASTKD4-sKO cells, processing defects were observed at the junction between ND2 and CO1 and at the ND5-CYTB junction. In addition, there was a processing defect at the region between ND1 and ND2 (Fig 3B), consistent with the reduction of these two mRNAs (Fig 3A). In the FASTKD5-sKO cells, the processing defect at the ATP8/6-CO3 junction was most pronounced (Fig 3B), consistent with the northern blotting data (Fig 2B and 2D). However, we also observed that in the absence of FASTKD5 the processing of the ND5-CYTB junction and the 5′ UTR of CO1 were also impaired (Fig 3B).

An investigation into the effects of the FASTKD3&4-dKO on RNA processing revealed processing defects at the junction between ND2 and CO1 and at the ND5-CYTB junction, similar to the FASTKD4-sKO (Fig 3B), indicating that the primary processing role of FASTKD4 may be at these non-canonical junctions. Interestingly, the processing defect found at the junction between ND1 and ND2 in the FASTKD4-sKO cells, was absent in the FASTKD3&4-dKO, suggesting that the loss of FASTKD3 might compensate for the absence of FASTKD4 at this cleavage site. These findings thus provide evidence for partially overlapping roles of the FASTKD proteins in mtRNA processing. The greatest enrichment of unprocessed RNA precursors was observed in the FASTKD4&5-dKO cells; the most prominent of these defects was at the junction between ND5 and CYTB, while significant changes were also seen in the ND1-ND2 junction, the 5′ UTR of CO1, the ATP8/6-CO3 junction, and the junction between ND4L/4 and ND5 (Fig 3B). These findings indicate that both FASTKD4 and FASTKD5 play a role in mtRNA processing at the ND1-ND2, ND4L/4-ND5 and ND5-CYTB junctions consistent with the data from northern blotting (Fig 2). On the other hand, the dKO cell lines revealed that FASTKD5 is exclusively responsible for the specific cleavage of the non-canonical junctions at the ATP8/6-CO3 junction and at the 5′ UTR of CO1. Rapid amplification of cDNA ends (RACE) and sequencing confirmed that cleavage at the 5′ UTR of CO1 requires FASTKD5, since the precursor CO1 transcript was captured in the FASTKD5-sKO and FASTKD4&5-dKO cells but not in the WT and FASTKD4-sKO cells (S5A and S5B Fig). The control 5′ end of CO2 was unaffected in all tested cell lines (S5C Fig). This finding was further validated by northern blotting against the antisense tRNAY, that precedes the CO1 transcript, which showed an increase of the precursor CO1 transcript in cells lacking FASTKD5 compared to the WT and FASTKD4-sKO cells (S5D Fig). Similarly, the precursor CO1 transcript was present in cells lacking FASTKD5, while mature CO1 mRNA was only detected in the WT and FASTKD4-sKO cells (S5D Fig). Furthermore, the uncleaved precursors that were observed at the ATP8/6-CO3 junction in the FASTKD5-sKO cells were reduced in the FASTKD4&5-dKO cells.

It is interesting to note that processing of the normally tRNA-punctuated junctions between the rRNAs was not affected by the loss of any of the FASTKD3-5 proteins (Fig 3C), suggesting that these proteins likely participate in the downstream processing of non-canonical junctions, and possibly act downstream of MRPP3 and ELAC2. Their loss may nevertheless stimulate a general response to defective processing because more efficient processing is observed at certain canonical MRPP3/ELAC2 processing sites, such as tRNAT, in their absence (Fig 3B).

These data also allowed us to investigate how the loss of each of the FASTKD3-5 proteins affected the non-coding regions of the mitochondrial transcriptome (Fig 3B). Loss of FASTKD4 resulted in the accumulation of transcripts or junction-containing RNAs that are antisense to the ND2, CO2, ATP8/6 and CO3 mRNAs, whereas loss of FASTKD5 caused the accumulation of the CO1 antisense RNA (Fig 3B). The FASTKD3&4-dKO cells resulted in an accumulation of the same ncRNAs found in the FASTKD4-sKO cells, suggesting that FASTKD4 plays the predominant role in the removal of these antisense transcripts. In the case of the antisense ATP8/6, this is the only transcript that accumulates in the FASTKD4&5-dKO cells but not in the FASTKD5-sKO cells. The increase of specific ncRNAs is in contrast to the reduction of their complementary mRNAs and may suggest that the FASTKD proteins have a role in the clearance of the antisense transcripts during RNA processing and that in the absence of FASTKD proteins, the antisense transcripts accumulate. Impaired clearance of antisense RNAs can cause processing defects and destabilization of their complementary mRNAs since the accumulated antisense transcripts may allow duplex formation, as we have shown previously [49]. This duplex potentially precludes the processing of mRNAs and reduces their translation.

To investigate further the consequences of impaired processing of mtRNAs in the absence of the FASTKD proteins, we analyzed the effects on polyadenylation by mapping RNAseq reads to polyadenylated mRNA reference sequences identify changes in polyadenylation (Figs 4 and S6). We show that the polyadenylation is not affected in mRNAs, such as CO2, whose levels were not changed by the loss of specific FASTKD proteins, either in single or double KOs (Fig 4A). The polyadenylation status was also not affected in specific mRNAs, such as ATP8/6 (Fig 4B), even though its levels were changed in the KO cell lines compared to control cells, indicating that the loss of specific FASTKD proteins affects more the abundance rather than the polyadenylation status of these mRNAs. The polyadenylation of the ND5 mRNA without its 3’ UTR was reduced in the FASTKD4 and FASTKD5 KO cells (Fig 4C), but not the polyadenylation status of the ND5 mRNA with its 3’ UTR and the CYTB mRNA (S6 Fig).

Fig 4. Polyadenylation status of mitochondrial mRNAs in FASTKDs-KO cells.

Fig 4

Mapping of RNA-seq reads to polyadenylated mitochondrial mRNA reference sequences reveals no changes in CO2 (A) or ATP8/6 (B) mRNAs but a reduction in polyadenylation of ND5 mRNA was identified in the FASTKD4 and the FASTKD5 KO cell lines (C), compared to control cells. The numbering on the x-axis shows the mtDNA position of the transcript sequence and the canonical 3′ region of each mRNA is shown in dark grey. The predicted canonical cleavage site is marked with the dotted line, followed by numbering of the non-templated poly(A) residues shown in the light grey shading. The y axis shows the normalized read counts at each position.

FASTKD4 specifically binds to tRNAE, which is complementary to the ND5-CYTB RNA processing site

The transcriptome analysis of the FASTKDs-KO cell lines indicated that the FASTKD proteins are involved principally in the processing of non-canonical RNA junctions. Furthermore, these proteins, especially FASTKD4, may play a role in the elimination of ncRNAs. To understand how FASTKD4 could achieve its function, we performed a HITS-CLIP analysis to identify which RNA species are bound by FASTKD4 (Figs 5, S7A, and S7B). Using endogenous FASTKD4 as bait we found that FASTKD4 preferentially associates with mitochondrial tRNAE, which is encoded on the strand, opposite the ND5-CYTB junction (Figs 5A, S7A, and S7B). This preferential binding was confirmed by RT-qPCR (S7C Fig). Using UV cross-linked WT and FASTKD4-sKO HAP1 cells, we immunoprecipitated FASTKD4 from isolated mitochondria, purified the RNA from the immunoprecipitate, and performed RT-qPCR for various transcripts. We confirmed that mitochondrial tRNAE was enriched in the FASTKD4 immunoprecipitate (S7C Fig). However, we noticed that in addition to the tRNAE, other transcripts were also enriched which did not score positive in the HITS-CLIP analysis. This suggests that FASTKD4 associates more generally with unprocessed polycistronic transcripts in addition to the tRNAE, or possibly also interact with other transcripts. Curiously, we observed that the tRNAE level was not altered in FASTKD4-sKO cells even though the ND5-CYTB precursor on the heavy strand was shown to accumulate (S3G Fig).

Fig 5. FASTKD4 specifically binds to tRNAE complementary to the ND5-CYTB RNA processing site.

Fig 5

(A-B) Strand specific HITS-CLIP read counts corresponding to the 14600–14800 region of the mtDNA for anti-FASTKD4 antibody (A). The pie-chart in (B) shows the fraction of tRNAE reads that includes the last encoded position (A73) of tRNAE (grey) and reads that are truncated on the 3′ end of tRNAE (dark blue). The inset shows all reads that include A73 of tRNAE with the fraction of unprocessed RNAs containing an extended sequence (orange), the fraction of reads that end exactly at A73 (yellow), and the fraction of those that have a CCA addition (light blue).

The identification of preferential binding of FASTKD4 to the tRNAE is an intriguing result, given that this RNA is within the complementary sequence on the opposite strand of the ND5-CYTB junction, the processing of which is known to be impaired in the loss of FASTKD4. Around 40% of the HITS-CLIP reads covering tRNAE included the 3′ end of its coding sequence, namely A73, and the majority of these A73-containing reads additionally included a 3′ extension with the CCA tail (Fig 5B). This indicates that FASTKD4 can interact with the post-transcriptionally modified, CCA-containing mature tRNAE. However, the time course of this binding is still uncertain, as we do not know whether FASTKD4 binds tRNAE before or after its processing and maturation. Nevertheless, the binding of FASTKD4 to this specific region provides a mechanistic explanation for the role of FASTKD4 in the processing of the ND5-CYTB junction, as discussed later.

The FASTK family proteins are essential for expression of the mitochondrially encoded respiratory complex proteins

To investigate further the phenotypes of the FASTKDs-KO cell lines, we measured de novo mitochondrial translation in the presence of 35S-methionine and 35S-cysteine (Fig 6A). Loss of FASTKD3 caused a specific increase in ND3 protein synthesis compared to controls, which is consistent with an increase of ND3 mRNA (Figs 2B and 3A). FASTKD4-sKO cells showed a decrease in expression of the ND3 and COX3 proteins also in line with their mRNA levels. However, levels of newly synthesized ND5 and COX1 proteins were increased following the loss of FASTKD4 despite the low level of mature ND5 mRNA (Figs 2B, 2D, and 3B), and this was also found in the FASTKD3&4-dKO cells (Fig 6A). The reason for the poor correlation between mRNA level and protein translation in this case is currently unclear. On the other hand, we do not understand why COX1 translation is increased in the absence of FASTKD4, given that the CO1 mRNA level is not affected. This suggests that in addition to playing some role in RNA processing, FASTKD4 may also participate in the control of translation of specific mRNAs as it associates with factors that modulate RNA metabolism and translation such as LRPPRC and IARS2 (S8 Fig). Finally, the absence of FASTKD4 was found to normalize the level of ND3 mRNA (Figs 2B and 3A) and protein (Fig 6A), which was upregulated in FASTKD3-sKO cells. This is consistent with our earlier conclusion that, at least in this specific case, FASTKD4 can compensate for the loss of FASTKD3.

Fig 6. Effect of FASTK family protein depletion on mitochondrial translation, respiratory chain assembly and oxygen consumption.

Fig 6

(A) Levels of de novo mitochondrial protein synthesis were measured in WT (control) and FASTKDs-KO HAP1 cells by pulse incorporation of 35S-labeled methionine and cysteine. Equal amounts of whole cell lysates were separated by SDS-PAGE and visualized by autoradiography. (B) Protein expression levels of specific subunits of each of the MRC complexes in WT (control) and FASTKDs-KO cells were evaluated by immunoblotting. Total OXPHOS Rodent WB Antibody Cocktail antibody was used to assess the efficiency of the MRC complex assembly. VDAC1 was included as a mitochondrial loading control. (C) Relative abundance of each assembled MRC complex was determined by quantification of the results of immunoblotting (n = 3). Loading amounts were normalized relative to VDAC1. The dotted line shows the relative abundance of control (= 1). Results are mean±SEM, *P<0.05, **P 0.001 to 0.01, ***P <0.001 (two-tailed unpaired t-test). (D) Oxygen consumption rate (OCR) in WT (control) and FASTKDs-KO cells was measured using the Seahorse analyzer. OCR was normalized to the number of cells in each well. A representative result from three independent biological experiments is shown.

Loss of FASTKD5 caused a reduction in protein synthesis of COX1, COX3 and ATP6 (Fig 6A) consistent with their decreased mRNA levels, as well as reduced COX2 translation, which was not correlated with a change in mRNA abundance (Figs 2B and 3A). Remarkably, COX1 protein synthesis was strongly perturbed in the cells lacking FASTKD5, consistent with the severe defect in pre-CO1 RNA processing (Figs 2B, 2D, and 3B). ND5 protein synthesis was not affected in the FASTKD5-sKO, which probably reflects the minor involvement of FASTKD5 in the processing of the ND5-CYTB junction (Figs 2A, 2D, and 3B). It is striking that, while the correctly processed ND5 mRNA level is almost undetectable in the FASTKD4&5-dKO cells (Fig 2), the level of ND5 protein was normal (Fig 6A). These results support the hypothesis that, at least for ND5, the protein may be translated from the ND5-CYTB precursor RNA.

Consistent with these results, using an antibody cocktail that recognizes subunits from all mitochondrial respiratory complexes (MRC) to assess their abundance, we found that Complex IV was most affected by the loss of FASTKD5 (Fig 6B and 6C). This result was validated by oxygen consumption measurements of the different KO cells (Fig 6D). We found that both FASTKD4-sKO and FASTKD3&4-dKO cells had only minor defects in OXPHOS. In contrast, oxygen consumption was dramatically reduced in both the FASTKD5-sKO and the FASTKD4&5-dKO cells. These findings indicate that FASTKD5 is indispensable for OXPHOS because it is essential for COX1 protein synthesis and the assembly of Complex IV.

Discussion

Post-transcriptional control of human mitochondrial gene expression is regulated in time and space, with many events occurring within the mitochondrial RNA granules [20,50]. Dysfunction of these post-transcriptional events can lead to numerous, often severe, mitochondrial pathologies [34,51]. Here, we have characterized the FASTK family proteins that are emerging as key post-transcriptional regulators of mitochondrial gene expression, and we have focused on their roles in mtRNA processing. Their function in non-canonical mtRNA processing is evolutionarily conserved. C. elegans is an ancestral model organism that has only one FASTK orthologue, FASK-1 (FASTK-related protein 1), to which mammalian FASTKD4 is the most closely related [18]. Deletion of the fask-1 gene resulted in a specific accumulation of ND5-containing precursor transcripts (16S-ND3-ND5 and ND3-ND5), which lack tRNA junctions, and a decrease in mature ND5 mRNA (S9 Fig).

Mitochondrial transcriptome analyses of HAP1 cell lines carrying single or double knockouts of FASTKD3-5, revealed that FASTKD4 and FASTKD5 control the maturation and abundance of a broad range of mitochondrial mRNAs, and furthermore, they also affect the fate of many of the ncRNAs in the mitochondrial transcriptome. The loss of FASTKD4 resulted in impaired ND5-CYTB RNA processing, and the absence of FASTKD5 caused defects in ND5-CYTB, pre-CO1, and ATP8/6-CO3 RNA processing, as previously reported [18,19]. None of these effects were seen in cells depleted of FASTKD3. The defective processing of the ND5-CYTB junction was observed in the single KOs of FASTKD4 and FASTKD5, and the effect persisted in the double mutant FASTKD4&5-dKO, suggesting that FASTKD4 and FASTKD5 may cooperate to ensure optimal processing of this junction. However, the interactions between members of the FASTK family can be more complex since we revealed antagonistic activities in the processing, or stabilization of some mRNAs. For instance, the ND3 mRNA level was significantly increased in the FASTKD3-sKO and FASTKD5-sKO cells but decreased in the FASTKD4-sKO cells compared to controls. Interestingly, in both dKO cell lines (FASTKD3&4-dKO and FASTKD4&5-dKO), the ND3 mRNA level was reduced, indicating that FASTKD4 may play the predominant role in regulating the expression of the ND3 mRNA. It is interesting to note that the processing of tRNAG and tRNAR, which are tRNAs that flank ND3, was boosted in the FASTKD3-sKO and the FASTKD5-sKO, whereas this was not observed in the FASTKD4-sKO and the dKO cells, suggesting that FASTKD4 increases the stability of ND3 mRNA after it is cleaved from its precursor transcript.

The complex interactions between FASTKD members are also illustrated by the interdependence of FASTKD3 and FASTKD5 in terms of their mutual stability. Loss of one member of the family leads to a lower expression of the other, suggesting a close physical interaction between them, as is found for other proteins that show a similar interdependence [4244]. However, we did not detect an interaction between FASTKD3 and FASTKD5 in the BioID analysis (S8 Fig). It is important to note that this inconsistency may be cell-type specific effects since 143B cells, which we used in the BioID analysis, express FASTKD2 protein unlike HAP1 cells (S3A Fig), and the expression of FASTKD2 may dynamically reprogram protein interaction profiles of the FASTK protein family in these cells. Further experiments are required to test this hypothesis. On the other hand, the BioID analysis revealed a physical interaction between FASTKD4 and FASTKD5. These data taken together, provide evidence that FASTK family members may interact to form large protein complexes, capable of exerting a variety of regulatory functions, depending on the specific combination of the FASTKD, and possibly other protein components. Among the proteins affected by the loss of FASTKD family members, which may also participate in the formation of larger complexes, are the post-transcriptional tRNA processing and modifying enzymes, MRPP1 (TRMT10C), ELAC2 and RPUSD4. In addition, the BioID experiments using FASTKD4 and FASTKD5, identified several other interacting proteins such as LRPPRC and GRSF1, which could constitute further components of the protein machinery that is functionally linked to RNA processing (S8 Fig) [13]. This is supported by a recent study of mitochondrial protein interaction networks based on the BioID approach, which revealed that the FASTK family members and a subset of the mtRBPs, including those identified in this study, co-localize within the mitochondrial matrix [52].

De novo translation analyses revealed that the loss of the FASTKD proteins result in significant defects in mitochondrial translation and in mitochondrial respiration. Importantly, the extent of the defect in oxygen consumption was proportional to the effect on non-canonical RNA processing. These experiments on translation levels also revealed that the level of mRNA does not always reflect their translation efficiency. For instance, ND5 protein synthesis was normal or even higher in the FASTKD4-sKO and FASTKD4&5-dKO cells, despite the very low expression level of its mRNA. This suggests either a highly efficient translation of the residual ND5 mRNA or the possibility that ND5 can be translated from the increased levels of the ND5-CYTB precursor transcripts. In addition, ND4 protein synthesis was elevated in cells lacking FASTKD5, regardless of its mRNA level. These findings raise the hypothesis that FASTK family proteins can modulate mitochondrial translation.

The mitochondrial transcriptome analyses revealed that the FASTKD proteins are also involved in the cleavage of certain tRNA junctions such as the cluster of tRNAs between ND1 and ND2 and tRNAE between ncCYTB and ND6. This implies that the FASTKD proteins may recruit the tRNA processing enzymes at some specific sites. However, the processing of some other tRNA junctions, for example tRNAD between CO1 and CO2, were facilitated following the loss of the FASTKD proteins. These data show that the FASTKD proteins specifically facilitate or inhibit tRNA processing, which largely affects the metabolism of mRNAs.

The transcriptome analyses also indicated that FASTKD5 seems to be involved in the cleavage of the non-canonical junction between antisense ATP8/6 and CO3. In this case, a mechanism other than the recruitment of known RNA processing enzymes must be responsible, as knockout of MRPP3 and ELAC2 does not affect this site [1113]. For this event, FASTKD5 could exhibit its own intrinsic nuclease activity or recruit an as yet unidentified nuclease. Furthermore, northern blotting revealed that the processing or removal of some specific sncRNAs, sncATP8/6 and sncCO1, appears to be perturbed in cells lacking FASTKD4, suggesting that the FASTKD proteins may also be involved in ncRNA clearance. Furthermore, the FASTKD proteins can have opposing functions in RNA processing. This is evident with the proximal processing site of the 5’ UTR of CO1 that is impaired in the absence of FASTKD5, while this junction is efficiently processed in cells lacking FASTKD4. In the absence of FASTKD5, the precursor CO1 transcript containing the non-coding mirror tRNAY is specifically increased, indicating that FASTKD5 facilitates the cleavage of the junction between mirror tRNAY and the CO1 mRNA. These findings are consistent with the significant reduction in COX1 protein synthesis in the loss of FASTKD5, and the increase of COX1 translation in the absence of FASTKD4. The underlying cause could be the presence of a structured stem-loop at the 5′ end of CO1 that is not processed in the absence of FASTKD5, which obstructs mitoribosome recruitment and thereby inhibits its translation (Fig 7).

Fig 7. A model showing the proposed roles of FASTKD4 and FASTKD5 in the RNA processing of the 5′ UTR of CO1.

Fig 7

In the absence of FASTKD5, the proximal processing site of the 5′ UTR of CO1 cannot be resolved and obstructs mitoribosome binding, thereby precluding its translation. On the other hand, FASTKD4 facilitates the degradation of a cluster of mirror tRNAs (mirror tRNAY, tRNAC, tRNAN and tRNAA) that could play a regulatory role in COX1 translation.

We have shown that several ncRNAs are differentially regulated in the FASTKDs-KO cell lines, and curiously, our analyses reveal that like the coding transcripts, ncRNAs are clearly processed and in most cases their lengths are similar to the length of the complementary mRNA. This suggests that both strands may be cleaved simultaneously in the same reaction. To explain this observation, we propose two contrasting hypotheses. First, that the initial substrate for processing could be a dsRNA comprising the two long complementary polycistronic RNAs, and that only after initial cleavage of the dsRNA, would smaller fragments be separated by RNA helicases and subject to further maturation or degradation steps. Second, this could occur because antisense RNA sequences often fold into similar structures as their sense counterparts, such that “mirror” tRNAs and other complementary processing signals could be recognized by mitochondrial processing enzymes, as we have observed before for the RNase P complex [49].

A striking result from the HITS-CLIP analysis revealed that FASTKD4 preferentially binds to mitochondrial tRNAE, which is complementary to the ND5-CYTB RNA processing site. Binding of FASTKD4 could prevent tRNAE from forming a duplex with its complementary region, which would have an inhibitory effect on ND5-CYTB RNA processing. If binding to RNA occurs prior to the processing of tRNAE, FASTKD4 may bind to the tRNAE precursor transcripts containing ND6 and its long 3′ UTR and may regulate the processing of other light strand transcripts encoded in the 3′ UTR of ND6 including ncND5, ncND4L/4, ncND3, ncCO3, ncATP8/6, and ncCO2. Alternatively, the binding of FASTKD4 to tRNAE may reflect the possibility that this protein could, in addition to RNA processing, be involved in translation, given that a mitoribosomal protein MRPS27 also preferentially binds tRNAE as we have previously shown [53].

In conclusion, we have shown that FASTKD3, FASTKD4 and FASTKD5 regulate the expression of a broad range of mitochondrial transcripts, including ncRNAs, through controlling the processing and clearance of specific canonical and non-canonical junctions. We propose a new model, shown in Fig 7, whereby the orchestrated roles of FASTKD4 and FASTKD5 are crucial for the processing of the non-canonical pre-CO1 mRNA in mitochondria by FASTKD5-mediated cleavage and removal of non-coding RNAs from that region by FASTKD4 that can regulate the translational efficiency of CO1.

Materials and methods

Cell culture

143B cells were cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin in 5% CO2 at 37°C. HeLa cells were cultured in DMEM supplemented with 10% FBS in 5% CO2 at 37°C. HAP1 cells were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 4 mM L-glutamine, 25 mM HEPES, 3.024 g/L NaHCO3, 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin, 100 mg/ml streptomycin, 1 mM sodium pyruvate, and 50 μg/ml uridine in 5% CO2 at 37°C.

Generation of CRISPR/Cas9 knockout cells

To generate FASTKDs-KO cells, we used Multiplex CRISPR/Cas9 Assembly Systems (Addgene Kit #1000000055) [54]. A single gRNA was cloned into pX330A or pX330S, and three gRNAs (FASTKD3, FASTKD4, and FASTKD5) were cloned into pX330A-1x3 following to the inventor’s protocol [54]. Co-transfection of HAP1 cells with the appropriate gRNA constructs together with a GFP expression plasmid (pCI-GFP) was performed using Lipofectamine LTX (Invitrogen) according to the manufacturer’s instructions. 24 h after transfection, GFP positive cells were selected by fluorescence activated cell sorting (FACS) using the Beckman Coulter MoFlo Astrios, and single cells were plated into individual wells of a 96-well plate. Screening of clones was performed by Sanger sequencing and immunoblot analyses.

Northern blotting

Northern blot analyses were performed as previously described [55]. Briefly, 10 μg of total cellular RNA prepared using the TRIzol reagent was separated on denaturing formaldehyde 1% agarose gel for mRNAs and rRNAs, or 10% polyacrylamide gel containing 7 M urea for tRNAs. RNAs were transferred to Hybond-N+ hybridization membranes (Sigma) and UV-crosslinked to the membrane. Membranes were hybridized with T7-transcribed [α-32P] UTP radiolabeled riboprobes. Hybridization was carried out overnight at 65°C in 50% formamide, 7% SDS, 0.2 M NaCl, 80 mM sodium phosphate (pH 7.4), and 100 mg/ml salmon sperm DNA. Imaging and quantification were performed using the Typhoon imaging system (GE Healthcare). Primers used for the preparation of PCR templates for the transcription of the riboprobes are listed in S1 Table. Northern blotting of the 5’ UTR of the CO1 mRNA was performed as previously described [12,13]. The following biotinylated oligonucleotide probes were used: /52-Bio/ (5’ dual biotin modification)- atggctgagtgaagcattggac (antisense tRNAY), ggagaagatggttaggtctacg (CO1 mRNA), and cctacggaaaccttgttacgac (18S rRNA).

Measurement of respiratory chain activity

Measurement of oxygen consumption was performed using a Seahorse XFe24 Flux Analyzer (Seahorse Biosciences). 60,000 HAP1 cells were seeded into XF24 cell culture microplates coated with 0.01% poly-L-lysine solution (Sigma) and grown overnight. Cells were incubated at 37°C for 1 h in Dulbecco’s PBS with MgCl2 and CaCl2 (Sigma D8662) supplemented with 5 mM sodium pyruvate. Basal oxygen consumption was measured before further treatment. At the times indicated, the following compounds were injected: oligomycin (final concentration 2 μM), FCCP (final concentration 1 μM), rotenone and antimycin A (final concentration 1 μM each). Each measurement loop consisted of 30 s mixing, 1 min waiting, and 2 min measuring oxygen consumption. After the measurement, the number of cells was counted for normalization.

Preparation of whole cell lysates and mitochondria-enriched fractions

Whole cell lysates (WCLs) were prepared by lysing cells in RIPA lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, and an in-house protease inhibitor cocktail) for 30 min on ice followed by centrifugation at 16,000 g for 10 min at 4°C in order to remove insoluble material. For preparation of the mitochondria-enriched fraction, cell fractionation was carried out on ice in MB buffer (10 mM HEPES pH 7.4, 210 mM mannitol, 70 mM sucrose, 1 mM EDTA, and the in-house protease inhibitor cocktail) following 30 passages through a 25G x 1" Microlance needle (BD, 300400). Nuclei and unbroken cells were discarded after centrifugation at 2,000 g. The mitochondria-enriched fraction was then recovered by centrifugation at 10,000 g. Protein content was determined using the BCA Protein Assay Kit (Pierce).

Immunoblotting and dot blotting

Equal amounts of protein were analyzed by SDS-PAGE. For Immunoblotting, proteins were transferred electrophoretically to nitrocellulose or PVDF membranes (GE Healthcare) and exposed to the primary antibodies specified below. The blots were further incubated with anti-goat, anti-rabbit or anti-mouse HRP-conjugated secondary antibodies (Dako) as appropriate, and visualized using ECL. For dot blots, the mitochondria-enriched fractions were lysed on ice for 30 min in 50 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.5% NP40, in-house protease inhibitor cocktail, and 1U/μL RNasin Plus RNase Inhibitor (Promega). Soluble material was collected following centrifugation for 30 min at 21,000 g. Equal amount of protein were spotted onto a nitrocellulose membrane (GE Healthcare). The membrane was exposed to antibodies and signals were visualized by chemiluminescence. The following primary antibodies were used: anti-FASTK (Abcam, ab97544), anti-FASTKD2 (Proteintech, 17464-1-AP), anti-FASTKD3 (Sigma-Aldrich, sab2701102), anti-FASTKD4 (Proteintech, 16245-1-AP), anti-FASTKD5 (Sigma-Aldrich, sab2700438), anti-dsRNA (J2; Scicons, 10010200), anti-mtHSP70 (Invitrogen, MA3-028), anti-VDAC1 (Santa Cruz, sc-8829), anti-γ tubulin (Santa Cruz, sc-17787), anti-GRSF1 (Atlas antibodies, HPA036985), anti-LRPPRC (Santa Cruz, sc-166178), anti-PNPT1 (Santa Cruz, sc-365049), anti-DHX30 (Abcam, ab85687), anti-RPUSD4 (Abcam, ab122571), anti-SUV3 (Santa Cruz, sc-365750).

Immunofluorescence

Immunofluorescence analyses were performed on cells fixed in 4% paraformaldehyde for 15 min. Cell permeabilization and blocking were performed together by incubating the fixed cells in PBS containing 0.3% Triton X-100 and 1% pre-immune goat serum for 45 min. The same buffer was used to incubate cells with the specified primary antibody. After 90 min incubation, the cells were washed in PBS and incubated with the appropriate secondary antibody conjugated with AlexaFluor 488 or Alexa 594 (Life Technologies). Mitochondrial networks and nascent transcripts were stained respectively using MitoTracker Red FM (Thermo Fisher Scientific), and 5 mM BrU (Sigma) as previously described [16]. Imaging was performed using a Zeiss LSM700 confocal microscope equipped with a 63× oil objective. All images were imported into ImageJ and uniformly adjusted for brightness and contrast. The following primary antibodies were used: anti-SSBP1 (Proteintech, 12212-1-AP), anti-BrU (Roche, 11170376001), anti-dsRNA (J2; Scicons, 10010200).

RNA-seq

RNA sequencing was performed on total RNA from three control and three of each of the five FASTKD knockout cell lines, using the Illumina NovaSeq platform, according to the Illumina Tru-Seq protocol as described previously [12,13,29]. Raw reads were trimmed of adapter sequences using cutadapt v1.18 [56] with standard parameters. Trimmed reads were mapped against the NuMTS masked human genome sequence (Hg38) using STAR v2.7.3a [57] and GENCODE v34 gene annotation with a customized mitochondrial annotation. Salmon v1.2.1 [58] (-l ISR–seqBias—-gcBias) in alignment based mode was used to quantify gene expression from the transcriptome alignments produced by STAR with a sequence file produced by gffread v0.11.7 [59]. Strand-specific coverage of the primary alignments of properly paired, full-length RNA fragments (excluding those with a length > 500 nt) across the mitochondrial genome was calculated with samtools v1.10 [60] and bedtools genomecov v2.26.0 [61], normalised to library size. Differential expression analysis was performed with DESeq2 by counts summarized with tximport [62].

Poly(A) analyses

Sequenced reads were aligned against the human mitochondrial transcriptome bowtie2 v2.4.1 (—nofw—fr) [63] using the GENCODE v34 transcript set combined with custom mitochondrial rRNA and mRNA sequences with an additional 50 adenine residues added to the 3′ ends to allow mapping of polyA tails as we have described previously [64]. Properly paired alignments normalized to library size were calculated with samtools v1.10 [60] and bedtools genomecov v2.26.0 [61]. Gene-level normalized coverage profiles were extracted and lengths of poly(A) tails analyzed [61,64].

BioID

Using the GAL4/UAS expression system, 4-hydroxytamoxifen (4-OHT) inducible 143B cells were generated for temporal control of protein expression of FASTKD4 or FASTKD5 tagged with BirA (R118G)-Flag at the C-terminus [65]. Briefly, the FASTKD4 or FASTKD5 coding sequence tagged with C-terminal BirA (R118G)-Flag was cloned into pF 5xUAS plasmid (a kind gift from Prof. John Silke, The Walter and Eliza Hall Institute of Medical Research) [65]. Plasmids were packaged into lentivirus and used to infect 143B cells containing a genomic GAL4-ERT2-VP16 cassette. Cells were selected using 3 mg/ml puromycin. Protein expression was induced following addition of 100 nM 4-OHT for 24 h and biotinylation was then induced by addition of 50 μM biotin for 1 h. Mitochondria were extracted from cells to minimize contamination with free biotin, and subjected to pulldown experiments following to the previously published protocol [66] with the following minor modifications: mitochondria were lysed on ice for 30 min without sonication; and proteins were eluted in 1x Laemmli buffer by heating at 95°C for 10 min and further analyzed by LC-MS/MS.

LC-MS/MS

Peptides were desalted on C18 StageTips [67] and dried by vacuum centrifugation prior to LC-MS/MS injections. Samples were resuspended in 2% acetonitrile, 0.1% FA and nano-flow separations were performed on a Dionex Ultimate 3000 RSLC nano UPLC system connected in-line with a Lumos Fusion Orbitrap Mass Spectrometer. A capillary precolumn (Acclaim Pepmap C18, 3 μm-100 Å, 2 cm x 75 μm ID) was used for sample trapping and cleaning. A 50 cm long capillary column (75 μm ID; in-house packed using ReproSil-Pur C18-AQ 1.9 μm silica beads; Dr. Maisch) was then used for analytical separations at 250 nl/min over 150 min biphasic gradients. Acquisitions were performed through Top Speed Data-Dependent acquisition mode using a cycle time of 1 s. Initial MS scans were acquired with a resolution of 240’000 (at 200 m/z) and the most intense parent ions were selected and fragmented by High energy Collision Dissociation (HCD) with a Normalized Collision Energy [68] of 30% using an isolation window of 0.7 m/z. Fragmented ions were acquired using the Ion Trap using a maximum injection time of 20 s. Selected ions were then excluded for the following 20 s. Raw data were processed using SEQUEST, MS Amanda and Mascot in Proteome Discoverer v.2.4 against a concatenated database consisting of the Uniprot Human protein database (73112 entries) and a FASTKD sequence. Enzyme specificity was set to trypsin and a minimum of six amino acids was required for peptide identification. Up to two missed cleavages were allowed. A 1% FDR cut-off was applied at both peptide and protein identification levels. For the database search, carbamidomethylation was set as a fixed modification, whereas oxidation (M), acetylation (protein N-term), PyroGlu (N-term Q), and Phosphorylation (S,T,Y) were considered as variable modifications. Data was further processed and inspected in Scaffold 4.10 (Proteome Software, Portland, USA) and spectra of interest were manually validated.

High-throughput sequencing of RNA isolated by cross-linking immunoprecipitation (HITS-CLIP)

Covalent bonds between endogenous FASTKD4 protein and RNA in HeLa cells were induced by irradiation with ultraviolet (UV) light (150 mJ/cm2). After cell collection, mitochondria were extracted by differential centrifugation. Pelleted mitochondria were lysed and the samples were incubated overnight with 5 μg anti-FASTKD4 (Proteintech, 16245-1-AP) or anti-HA (Roche, 11867423001) antibody as a control, in the presence of proteinase and ribonuclease inhibitors. Protein-antibody complexes were then bound to Pierce Protein G Magnetic Beads (Thermo) and while still on beads, RNA was partially digested with micrococcal nuclease (NEB) for 10 min at room temperature, in the presence of TURBO DNase. The reaction was stopped by adding 12 μl SUPERasin (ThermoFisher Scientific). After washing and elution of proteins from the beads, proteins were digested with 4 mg/ml Proteinase K. RNA was end repaired with Antarctic Phosphatase and T4 Polynucleotide Kinase and used for library generation, following the manufacturer’s protocol (TruSeq Small RNA library preparation kit (Illumina)). Indexed PCR product was run on a 6% PAGE TBE gel to remove adapter only fragments and purified with Zymo DNA Clean and Concentrator columns. Quality and concentration were assessed with a High Sensitivity D1000 Screentape for TapeStation (Agilent). Libraries were subjected to high-throughput sequencing using the Illumina HiSeq platform. For the qPCR analysis, the protein-RNA complexes were similarly immunoprecipitated from WT and FASTKD4-sKO HAP1 cells, then the RNA was recovered without digestion. Anti-Flag (Sigma, F7425) antibody was used as control.

Processing and mapping of HITS-CLIP data

Quality trimming and 3′-end adaptor clipping of sequenced reads were performed with Trim Galore!. Sequenced reads longer than 20 nt were aligned to the human reference genome (GRCh38) with Bowtie2 [63]. The alignment was split by template strand (Samtools) [60] and converted to BED files (Bedtools) [61], and peak calling was performed with Piranha [69].

Pulse labeling of mitochondrial translation

Pulse labeling experiments to evaluate mitochondrial translation were carried out as described previously [55]. Briefly, HAP1 cells were incubated for 20 min in methionine and cysteine-free DMEM supplemented with 10% heat-inactivated FBS, 110 mg/L sodium pyruvate, and 2 mM L-glutamine. 100 μg/ml emetine dihydrochloride was added for 5 min to inhibit cytosolic translation, followed by addition of 200 μCi/ml 35S-labeled methionine and cysteine mix (Perkin Elmer). Labelling was performed for 1 h, then cells were lysed. Equal amounts of each protein sample were resolved on 12–20% SDS-PAGE gels. Gels were stained with Coomassie Brilliant Blue to confirm equal loading, then dried and exposed. Imaging and quantification were performed with the Typhoon imaging system (GE Healthcare).

Quantitative PCR (qPCR) and Rapid amplification of cDNA ends (RACE)

Total cellular DNA purified by phenol-chloroform extraction was analyzed using GoTaq qPCR Master Mix (Promega) following the manufacturer’s instructions. For RT-qPCR, cDNA was prepared from DNase-treated RNA using the GoScript Reverse Transcriptase (Promega) with random primers (Promega, C118A) or RNA-specific primers for strand-specific qPCR. Primers used for RT and qPCR are listed in S1 Table. RACE was carried out as previously described in [49].

C. elegans strain generation and culture

C. elegans strains were maintained on OP50 plates using standard conditions at 20°C. N2 (Bristol strain) was used as a wild type, and the deletion allele fask-1(uge100) (strain FAS150) was derived from this background, using CRISPR/Cas9 as described [70]. The deletion allele is described in S8A Fig. The sgRNAs targeted the following genomic sequences: atatctagaatgtggagccgtgg, cccacgctttgcaggacgattcc, tttcagaacacagaaacgagcgg, and ccgctggcttcgatccagtagtc (PAM sequences are underlined). The deletion allele was identified by single worm PCR and sequenced with the primers oFSa0222 (agtcatggatgcagcgaaag) and oFSa0223 (gtggtgtcagagtgtctcat). For RNA analysis, worms from eight 9-cm nematode growth medium plates containing mostly adult, embryo and young larval stages were washed three times with PBS. Worms were pelleted after each wash by centrifugation for 2 min at 1000 g, and the washed worm pellets were resuspended in 2 ml Trizol reagent and frozen at -80°C.

Supporting information

S1 Fig. Sequence analysis of the FASTKDs-KO genes in the HAP1 cell lines.

Genomic modifications shown in (A) were detailed in (B).

(TIF)

S2 Fig. RNA-seq of the FASTKDs-KO genes in the HAP1 cell lines.

Specific deletions in each of the targeted FASTKD genes in each of the HAP1 cell lines relative to the control HAP1 cell line were shown.

(TIF)

S3 Fig. Characterization of the FASTKDs-KO HAP1 cell lines.

(A) Protein expression levels in 143B (control) and WT HAP1 cells were assessed by immunoblotting. Whole cell lysates (WCL) and mitochondria extracted from the cells were analyzed. mtHSP70 was used as a loading control. (B) mRNA expression levels in 143B (control) and WT HAP1 cells were analyzed by RT-PCR. (C) Relative abundance of 7S RNA in WT (control) and FASTKDs-KO HAP1 cells were quantified by RT-qPCR (n = 4). The amounts of 7S RNA were normalized by GAPDH. (D) The relative abundance of mtDNA in the FASTKDs-KO cells compared to controls was measured by qPCR and normalized to total nuclear DNA (n = 3). (E) WT and FASTKDs-KO HAP1 cells were labeled with BrU, MitoTracker Red, and DAPI, and immunolabeled with anti-SSBP1, anti-BrU and J2 anti-dsRNA. Immunofluorensce was analyzed by confocal microscopy. Scale bars indicate 20 μm. (F) The amount of mitochondrial dsRNA in the FASTKDs-KO cells and controls was measured by dot blotting. VDAC1 protein was used as a loading control. (G) Steady-state levels of mitochondrial tRNAs in WT (control) and FASTKDs-KO HAP1 cells were measured by northern blotting. 5S was analyzed as a loading control.

(TIF)

S4 Fig. The steady-state levels of rRNAs, mRNAs and ncRNAs in WT and FASTKDs-KO HAP1 cells measured by northern blotting.

Related to Fig 2. Two entire gels/exposures are shown. 5S and 7SL were used as loading controls. Equal amounts of total cellular RNA were loaded on the gel. Independent biological samples were analyzed per genotype. The pair of WT #2 and FASTKD4-sKO (A), a pair of WT #2 and FASTKD3&4-dKO (A), a pair of WT #1 and FASTKD4&5-dKO (B), and a pair of WT #3 and FASTKD3-sKO (B) are also shown in Fig 2A.

(TIF)

S5 Fig. Rapid amplification of cDNA ends (RACE) and northern blotting of the 5′ UTR of the CO1 mRNA.

(A) RACE of the 5′ UTR of CO1 mRNA in WT (control) and FASTKDs-KO HAP1 cells. (B) Sanger sequencing of the 5′ UTR of CO1 mRNA from WT HAP1 cells. (C) RACE of the 5′ end of CO2 mRNA in WT (control) and FASTKDs-KO HAP1 cells. (D) Northern blotting of RNA isolated from WT (control) and FASTKDs-KO HAP1 cells against the antisense tRNAY, CO1 mRNA, and 18S rRNA that was used as a loading control.

(TIFF)

S6 Fig. Polyadenylation status of mitochondrial mRNAs.

Related to Fig 4. Mapping of RNA-seq reads to polyadenylated mitochondrial mRNA reference sequences was used to analyze the polyadenylation status of mRNAs in the FASTKDs-KO cell lines compared to controls. The canonical 3′ region of each mRNA is shown in dark grey and the section of polyadenosine is shown in light grey.

(TIF)

S7 Fig. FASTKD4 specifically binds to tRNAE.

Related to Fig 5. (A-B) Strand specific HITS-CLIP read counts corresponding to the 13401–16569 region of the mtDNA for control (anti-HA antibody) (A) and anti-FASTKD4 antibody (B). (C) The tRNAE enriched through FASTKD4 immunoprecipitation from WT and FASTKD4-sKO HAP1 cells was quantified by strand-specific RT-qPCR. Anti-Flag antibody was used a s control. A representative result from two independent biological experiments is shown.

(TIF)

S8 Fig. BioID interactome analyses of FASTKD4 and FASTKD5.

Log2FC (FASTKD4-BirA/control) (A) or Log2FC (FASTKD5-BirA/control) (B) was plotted against a sum of normalized total spectra. Only significantly enriched proteins are shown (Log2FC ≥ 1). Cells that do not express the bait protein were used as control. Mitochondrial proteins are shown in blue. Red dot represents BirA-tagged bait proteins. (C-D) Gene ontology analysis (GO—molecular function) of mitochondrial proteins identified by the BioID of FASTKD4 (C) and FASTKD5 (D). (E) Number of mitochondrial proteins found in either or both BioID data sets from FASTKD4 or FASTKD5.

(TIF)

S9 Fig. Function of the FASTK family proteins in the processing of tRNA-less junctions is evolutionarily conserved.

(A) A schematic representation of fask-1 (B0564.7) deletion allele generated using CRISPR/Cas9 technology. Two sgRNAs each were used to cleave the genomic DNA near the start codon and in the last exon of the FASK-1 locus. The deletion allele fask-1(uge100) contains a truncated start codon, a 26 bp insertion and a 3642 bp deletion that removes all of the FASK-1 coding sequence except 153 bp of the last exon. (B) The steady-state levels of mitochondrial transcripts in WT (control) and FASK-1 deletion strains were measured by northern blotting. Act-1 was used as a loading control.

(TIF)

S1 Table. List of oligonucleotides used in this study.

Sequences used for Gibson assembly are shown in bold. T7 promoter sequence is underlined.

(TIF)

Acknowledgments

We would like to thank all current and past members of the JCM lab for their helpful advice and intellectual input during the course of this work. We would also like to thank Prof. John Silke (The Walter and Eliza Hall Institute of Medical Research) for sharing plasmids, and Prof. Walter Rossmanith (Medical University of Vienna) and Kinsey Maundrell (University of Geneva) for helpful discussions about our results. We would additionally like to thank Romain Hamelin and Diego Chiappe (Proteomics Core Facility, EPFL) who carried out the LC-MS/MS.

Data Availability

RNA-seq datasets have been deposited in the NCBI GEO with accession numbers GSE156556 (HITS-CLIP) and GSE156260 (mitochondrial transcriptomics). The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD020993 and 10.6019/PXD020993. All other relevant data are within the manuscript and Supporting information.

Funding Statement

This work was supported by fellowships and project grants from the Swiss National Science Foundation (31003A_179421 to JCM and 31003A_175606 to FAS), the National Health and Medical Research Council (insert APP1154646, APP1154932, APP1159594 and APP1156747 to AF and OR), the Australian Research Council (DP170103000 to AF and OR), the Cancer Council of Western Australia (to AF), and Medical Research Council, UK (MC_UU_00015/4 to M.M.). DR and MS are supported by UWA Postgraduate Scholarships. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Schon EA, DiMauro S, Hirano M. Human mitochondrial DNA: roles of inherited and somatic mutations. Nat Rev Genet. 2012;13(12):878–90. doi: 10.1038/nrg3275 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.D’Souza AR, Minczuk M. Mitochondrial transcription and translation: overview. Essays Biochem. 2018;62(3):309–20. doi: 10.1042/EBC20170102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Gustafsson CM, Falkenberg M, Larsson NG. Maintenance and Expression of Mammalian Mitochondrial DNA. Annu Rev Biochem. 2016;85:133–60. doi: 10.1146/annurev-biochem-060815-014402 [DOI] [PubMed] [Google Scholar]
  • 4.Chujo T, Ohira T, Sakaguchi Y, Goshima N, Nomura N, Nagao A, et al. LRPPRC/SLIRP suppresses PNPase-mediated mRNA decay and promotes polyadenylation in human mitochondria. Nucleic Acids Res. 2012;40(16):8033–47. doi: 10.1093/nar/gks506 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Jiang S, Koolmeister C, Misic J, Siira S, Kuhl I, Silva Ramos E, et al. TEFM regulates both transcription elongation and RNA processing in mitochondria. EMBO Rep. 2019;20(6). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Rackham O, Mercer TR, Filipovska A. The human mitochondrial transcriptome and the RNA-binding proteins that regulate its expression. Wiley Interdiscip Rev RNA. 2012;3(5):675–95. doi: 10.1002/wrna.1128 [DOI] [PubMed] [Google Scholar]
  • 7.Hallberg BM, Larsson NG. Making proteins in the powerhouse. Cell Metab. 2014;20(2):226–40. doi: 10.1016/j.cmet.2014.07.001 [DOI] [PubMed] [Google Scholar]
  • 8.Holzmann J, Frank P, Loffler E, Bennett KL, Gerner C, Rossmanith W. RNase P without RNA: identification and functional reconstitution of the human mitochondrial tRNA processing enzyme. Cell. 2008;135(3):462–74. doi: 10.1016/j.cell.2008.09.013 [DOI] [PubMed] [Google Scholar]
  • 9.Brzezniak LK, Bijata M, Szczesny RJ, Stepien PP. Involvement of human ELAC2 gene product in 3’ end processing of mitochondrial tRNAs. RNA Biol. 2011;8(4):616–26. doi: 10.4161/rna.8.4.15393 [DOI] [PubMed] [Google Scholar]
  • 10.Reinhard L, Sridhara S, Hallberg BM. The MRPP1/MRPP2 complex is a tRNA-maturation platform in human mitochondria. Nucleic Acids Res. 2017;45(21):12469–80. doi: 10.1093/nar/gkx902 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Sanchez MI, Mercer TR, Davies SM, Shearwood AM, Nygard KK, Richman TR, et al. RNA processing in human mitochondria. Cell Cycle. 2011;10(17):2904–16. doi: 10.4161/cc.10.17.17060 [DOI] [PubMed] [Google Scholar]
  • 12.Siira SJ, Rossetti G, Richman TR, Perks K, Ermer JA, Kuznetsova I, et al. Concerted regulation of mitochondrial and nuclear non-coding RNAs by a dual-targeted RNase Z. EMBO Rep. 2018;19(10). doi: 10.15252/embr.201846198 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Rackham O, Busch JD, Matic S, Siira SJ, Kuznetsova I, Atanassov I, et al. Hierarchical RNA Processing Is Required for Mitochondrial Ribosome Assembly. Cell Rep. 2016;16(7):1874–90. doi: 10.1016/j.celrep.2016.07.031 [DOI] [PubMed] [Google Scholar]
  • 14.Ojala D, Montoya J, Attardi G. tRNA punctuation model of RNA processing in human mitochondria. Nature. 1981;290(5806):470–4. doi: 10.1038/290470a0 [DOI] [PubMed] [Google Scholar]
  • 15.Sanger F, Coulson AR, Barrell BG, Smith AJH, Roe BA. Cloning in single-stranded bacteriophage as an aid to rapid DNA sequencing. J Mol Biol. 1980;143(2):161–78. doi: 10.1016/0022-2836(80)90196-5 [DOI] [PubMed] [Google Scholar]
  • 16.Jourdain AA, Koppen M, Rodley CD, Maundrell K, Gueguen N, Reynier P, et al. A mitochondria-specific isoform of FASTK is present in mitochondrial RNA granules and regulates gene expression and function. Cell Rep. 2015;10(7):1110–21. doi: 10.1016/j.celrep.2015.01.063 [DOI] [PubMed] [Google Scholar]
  • 17.Xu F, Ackerley C, Maj MC, Addis JB, Levandovskiy V, Lee J, et al. Disruption of a mitochondrial RNA-binding protein gene results in decreased cytochrome b expression and a marked reduction in ubiquinol-cytochrome c reductase activity in mouse heart mitochondria. Biochem J. 2008;416(1):15–26. doi: 10.1042/BJ20080847 [DOI] [PubMed] [Google Scholar]
  • 18.Boehm E, Zaganelli S, Maundrell K, Jourdain AA, Thore S, Martinou JC. FASTKD1 and FASTKD4 have opposite effects on expression of specific mitochondrial RNAs, depending upon their endonuclease-like RAP domain. Nucleic Acids Res. 2017;45(10):6135–46. doi: 10.1093/nar/gkx164 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Antonicka H, Shoubridge EA. Mitochondrial RNA Granules Are Centers for Posttranscriptional RNA Processing and Ribosome Biogenesis. Cell Rep. 2015;10(6):920–32. doi: 10.1016/j.celrep.2015.01.030 [DOI] [PubMed] [Google Scholar]
  • 20.Jourdain AA, Popow J, de la Fuente MA, Martinou JC, Anderson P, Simarro M. The FASTK family of proteins: emerging regulators of mitochondrial RNA biology. Nucleic Acids Res. 2017;45(19):10941–7. doi: 10.1093/nar/gkx772 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Baltz AG, Munschauer M, Schwanhausser B, Vasile A, Murakawa Y, Schueler M, et al. The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. Mol Cell. 2012;46(5):674–90. doi: 10.1016/j.molcel.2012.05.021 [DOI] [PubMed] [Google Scholar]
  • 22.Castello A, Fischer B, Eichelbaum K, Horos R, Beckmann BM, Strein C, et al. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell. 2012;149(6):1393–406. doi: 10.1016/j.cell.2012.04.031 [DOI] [PubMed] [Google Scholar]
  • 23.Van Nostrand EL, Freese P, Pratt GA, Wang X, Wei X, Xiao R, et al. A large-scale binding and functional map of human RNA-binding proteins. Nature. 2020;583(7818):711–9. doi: 10.1038/s41586-020-2077-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Simarro M, Gimenez-Cassina A, Kedersha N, Lazaro JB, Adelmant GO, Marto JA, et al. Fast kinase domain-containing protein 3 is a mitochondrial protein essential for cellular respiration. Biochem Biophys Res Commun. 2010;401(3):440–6. doi: 10.1016/j.bbrc.2010.09.075 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Popow J, Alleaume AM, Curk T, Schwarzl T, Sauer S, Hentze MW. FASTKD2 is an RNA-binding protein required for mitochondrial RNA processing and translation. RNA. 2015;21(11):1873–84. doi: 10.1261/rna.052365.115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Wolf AR, Mootha VK. Functional genomic analysis of human mitochondrial RNA processing. Cell Rep. 2014;7(3):918–31. doi: 10.1016/j.celrep.2014.03.035 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Boehm E, Zornoza M, Jourdain AA, Delmiro Magdalena A, Garcia-Consuegra I, Torres Merino R, et al. Role of FAST Kinase Domains 3 (FASTKD3) in Post-transcriptional Regulation of Mitochondrial Gene Expression. J Biol Chem. 2016;291(50):25877–87. doi: 10.1074/jbc.M116.730291 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Arroyo JD, Jourdain AA, Calvo SE, Ballarano CA, Doench JG, Root DE, et al. A Genome-wide CRISPR Death Screen Identifies Genes Essential for Oxidative Phosphorylation. Cell Metab. 2016;24(6):875–85. doi: 10.1016/j.cmet.2016.08.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Perks KL, Rossetti G, Kuznetsova I, Hughes LA, Ermer JA, Ferreira N, et al. PTCD1 Is Required for 16S rRNA Maturation Complex Stability and Mitochondrial Ribosome Assembly. Cell Rep. 2018;23(1):127–42. doi: 10.1016/j.celrep.2018.03.033 [DOI] [PubMed] [Google Scholar]
  • 30.Zaganelli S, Rebelo-Guiomar P, Maundrell K, Rozanska A, Pierredon S, Powell CA, et al. The Pseudouridine Synthase RPUSD4 Is an Essential Component of Mitochondrial RNA Granules. J Biol Chem. 2017;292(11):4519–32. doi: 10.1074/jbc.M116.771105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Ghezzi D, Saada A, D’Adamo P, Fernandez-Vizarra E, Gasparini P, Tiranti V, et al. FASTKD2 nonsense mutation in an infantile mitochondrial encephalomyopathy associated with cytochrome c oxidase deficiency. Am J Hum Genet. 2008;83(3):415–23. doi: 10.1016/j.ajhg.2008.08.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Yoo DH, Choi YC, Nam DE, Choi SS, Kim JW, Choi BO, et al. Identification of FASTKD2 compound heterozygous mutations as the underlying cause of autosomal recessive MELAS-like syndrome. Mitochondrion. 2017;35:54–8. doi: 10.1016/j.mito.2017.05.005 [DOI] [PubMed] [Google Scholar]
  • 33.Wei X, Du M, Li D, Wen S, Xie J, Li Y, et al. Mutations in FASTKD2 are associated with mitochondrial disease with multi-OXPHOS deficiency. Hum Mutat. 2020. doi: 10.1002/humu.23985 [DOI] [PubMed] [Google Scholar]
  • 34.Boczonadi V, Ricci G, Horvath R. Mitochondrial DNA transcription and translation: clinical syndromes. Essays Biochem. 2018;62(3):321–40. doi: 10.1042/EBC20170103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Steczkiewicz K, Muszewska A, Knizewski L, Rychlewski L, Ginalski K. Sequence, structure and functional diversity of PD-(D/E)XK phosphodiesterase superfamily. Nucleic Acids Res. 2012;40(15):7016–45. doi: 10.1093/nar/gks382 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Izquierdo JM, Valcarcel J. Fas-activated serine/threonine kinase (FAST K) synergizes with TIA-1/TIAR proteins to regulate Fas alternative splicing. J Biol Chem. 2007;282(3):1539–43. doi: 10.1074/jbc.C600198200 [DOI] [PubMed] [Google Scholar]
  • 37.Simarro M, Mauger D, Rhee K, Pujana MA, Kedersha NL, Yamasaki S, et al. Fas-activated serine/threonine phosphoprotein (FAST) is a regulator of alternative splicing. Proc Natl Acad Sci U S A. 2007;104(27):11370–5. doi: 10.1073/pnas.0704964104 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Kleinknecht L, Wang F, Stube R, Philippar K, Nickelsen J, Bohne AV. RAP, the sole octotricopeptide repeat protein in Arabidopsis, is required for chloroplast 16S rRNA maturation. Plant Cell. 2014;26(2):777–87. doi: 10.1105/tpc.114.122853 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Rivier C, Goldschmidt-Clermont M, Rochaix JD. Identification of an RNA–protein complex involved in chloroplast group II intron trans-splicing in Chlamydomonas reinhardtii. EMBO J. 2001;20(7):1765–73. doi: 10.1093/emboj/20.7.1765 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Glanz S, Kuck U. Trans-splicing of organelle introns—a detour to continuous RNAs. Bioessays. 2009;31(9):921–34. doi: 10.1002/bies.200900036 [DOI] [PubMed] [Google Scholar]
  • 41.Jacobs J, Marx C, Kock V, Reifschneider O, Franzel B, Krisp C, et al. Identification of a chloroplast ribonucleoprotein complex containing trans-splicing factors, intron RNA, and novel components. Mol Cell Proteomics. 2013;12(7):1912–25. doi: 10.1074/mcp.M112.026583 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Coates PJ, Nenutil R, McGregor A, Picksley SM, Crouch DH, Hall PA, et al. Mammalian prohibitin proteins respond to mitochondrial stress and decrease during cellular senescence. Exp Cell Res. 2001;265(2):262–73. doi: 10.1006/excr.2001.5166 [DOI] [PubMed] [Google Scholar]
  • 43.Back JW, Sanz MA, De Jong L, De Koning LJ, Nijtmans LG, De Koster CG, et al. A structure for the yeast prohibitin complex: Structure prediction and evidence from chemical crosslinking and mass spectrometry. Protein Sci. 2002;11(10):2471–8. doi: 10.1110/ps.0212602 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Zangari J, Petrelli F, Maillot B, Martinou JC. The Multifaceted Pyruvate Metabolism: Role of the Mitochondrial Pyruvate Carrier. Biomolecules. 2020;10(7). doi: 10.3390/biom10071068 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Nicholls TJ, Minczuk M. In D-loop: 40 years of mitochondrial 7S DNA. Exp Gerontol. 2014;56:175–81. doi: 10.1016/j.exger.2014.03.027 [DOI] [PubMed] [Google Scholar]
  • 46.Borowski LS, Dziembowski A, Hejnowicz MS, Stepien PP, Szczesny RJ. Human mitochondrial RNA decay mediated by PNPase-hSuv3 complex takes place in distinct foci. Nucleic Acids Res. 2013;41(2):1223–40. doi: 10.1093/nar/gks1130 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Dhir A, Dhir S, Borowski LS, Jimenez L, Teitell M, Rotig A, et al. Mitochondrial double-stranded RNA triggers antiviral signalling in humans. Nature. 2018;560(7717):238–42. doi: 10.1038/s41586-018-0363-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Weber F, Wagner V, Rasmussen SB, Hartmann R, Paludan SR. Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J Virol. 2006;80(10):5059–64. doi: 10.1128/JVI.80.10.5059-5064.2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Rackham O, Shearwood AM, Mercer TR, Davies SM, Mattick JS, Filipovska A. Long noncoding RNAs are generated from the mitochondrial genome and regulated by nuclear-encoded proteins. RNA. 2011;17(12):2085–93. doi: 10.1261/rna.029405.111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Pearce SF, Rebelo-Guiomar P, D’Souza AR, Powell CA, Van Haute L, Minczuk M. Regulation of Mammalian Mitochondrial Gene Expression: Recent Advances. Trends Biochem Sci. 2017;42(8):625–39. doi: 10.1016/j.tibs.2017.02.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Suomalainen A, Battersby BJ. Mitochondrial diseases: the contribution of organelle stress responses to pathology. Nat Rev Mol Cell Biol. 2018;19(2):77–92. doi: 10.1038/nrm.2017.66 [DOI] [PubMed] [Google Scholar]
  • 52.Antonicka H, Lin ZY, Janer A, Aaltonen MJ, Weraarpachai W, Gingras AC, et al. A High-Density Human Mitochondrial Proximity Interaction Network. Cell Metab. 2020;32(3):479–97. doi: 10.1016/j.cmet.2020.07.017 [DOI] [PubMed] [Google Scholar]
  • 53.Davies SM, Lopez Sanchez MI, Narsai R, Shearwood AM, Razif MF, Small ID, et al. MRPS27 is a pentatricopeptide repeat domain protein required for the translation of mitochondrially encoded proteins. FEBS Lett. 2012;586(20):3555–61. doi: 10.1016/j.febslet.2012.07.043 [DOI] [PubMed] [Google Scholar]
  • 54.Sakuma T, Nishikawa A, Kume S, Chayama K, Yamamoto T. Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system. Sci Rep. 2014;4:5400. doi: 10.1038/srep05400 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Jourdain AA, Koppen M, Wydro M, Rodley CD, Lightowlers RN, Chrzanowska-Lightowlers ZM, et al. GRSF1 regulates RNA processing in mitochondrial RNA granules. Cell Metab. 2013;17(3):399–410. doi: 10.1016/j.cmet.2013.02.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet journal. 2011;17:10–2. [Google Scholar]
  • 57.Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21. doi: 10.1093/bioinformatics/bts635 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14(4):417–9. doi: 10.1038/nmeth.4197 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Pertea G, Pertea M. GFF Utilities: GffRead and GffCompare. F1000Res. 2020;9:304. doi: 10.12688/f1000research.23297.2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078–9. doi: 10.1093/bioinformatics/btp352 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26(6):841–2. doi: 10.1093/bioinformatics/btq033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi: 10.1186/s13059-014-0550-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9(4):357–9. doi: 10.1038/nmeth.1923 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Siira SJ, Spahr H, Shearwood AJ, Ruzzenente B, Larsson NG, Rackham O, et al. LRPPRC-mediated folding of the mitochondrial transcriptome. Nat Commun. 2017;8(1):1532. doi: 10.1038/s41467-017-01221-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell. 2007;131(4):682–93. doi: 10.1016/j.cell.2007.10.037 [DOI] [PubMed] [Google Scholar]
  • 66.Roux KJ, Kim DI, Burke B. BioID: a screen for protein-protein interactions. Curr Protoc Protein Sci. 2013;74:19 23 1–19 23 14. doi: 10.1002/0471140864.ps1923s74 [DOI] [PubMed] [Google Scholar]
  • 67.Rappsilber J, Mann M, Ishihama Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc. 2007;2(8):1896–906. doi: 10.1038/nprot.2007.261 [DOI] [PubMed] [Google Scholar]
  • 68.Gaur R, Grasso D, Datta PP, Krishna PD, Das G, Spencer A, et al. A single mammalian mitochondrial translation initiation factor functionally replaces two bacterial factors. Mol Cell. 2008;29(2):180–90. doi: 10.1016/j.molcel.2007.11.021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Uren PJ, Bahrami-Samani E, Burns SC, Qiao M, Karginov FV, Hodges E, et al. Site identification in high-throughput RNA-protein interaction data. Bioinformatics. 2012;28(23):3013–20. doi: 10.1093/bioinformatics/bts569 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Arribere JA, Bell RT, Fu BX, Artiles KL, Hartman PS, Fire AZ. Efficient marker-free recovery of custom genetic modifications with CRISPR/Cas9 in Caenorhabditis elegans. Genetics. 2014;198(3):837–46. doi: 10.1534/genetics.114.169730 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Gregory S Barsh, Christoph Freyer

7 Jun 2021

Dear Dr Ohkubo,

Thank you very much for submitting your Research Article entitled 'The FASTK family proteins fine-tune mitochondrial RNA processing' to PLOS Genetics.

The manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the current manuscript. Based on the reviews, we will not be able to accept this version of the manuscript, but we would be willing to review a much-revised version. We cannot, of course, promise publication at that time.

Should you decide to revise the manuscript for further consideration here, your revisions should address the specific points made by each reviewer. We will also require a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

If you decide to revise the manuscript for further consideration at PLOS Genetics, please aim to resubmit within the next 60 days, unless it will take extra time to address the concerns of the reviewers, in which case we would appreciate an expected resubmission date by email to plosgenetics@plos.org.

If present, accompanying reviewer attachments are included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our Submission Checklist.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please be aware that our data availability policy requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as "data not shown" or "unpublished results" in manuscripts. All points should be backed up by data provided with the submission.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool.  PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

PLOS has incorporated Similarity Check, powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, use the link below and 'Revise Submission' in the 'Submissions Needing Revision' folder.

[LINK]

We are sorry that we cannot be more positive about your manuscript at this stage. Please do not hesitate to contact us if you have any concerns or questions.

Yours sincerely,

Christoph Freyer, PhD

Guest Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

Guest editor comments:

· Given the haploid state of the cell line used, I would appreciate if you could clarify why the identified FASTKD5 variant in the FASTKD3/4-dKO cells is deemed as irrelevant to the experiments. The Western blot in Figure 1 would suggest otherwise.

· The conclusions of the Northern blot experiments in figure 2 seem to be based on statistical significance, rather than physiological relevance. Some of the signals are very low, making quantification difficult, increasing variation and therefore potentially skewing the conclusions. The lack of error bars for WT samples in figures 2B-E, makes interpretation more difficult. This is especially true for some of the nc and sncRNA species. It woudl be helpful in some cases, such as for ND6 or ncND3, to indicate what parts of the blot were used for quantification.

· Please ensure the readers in the figure legend that the presented gel sections in figure 2A stem from the same representative gel and not from different gels. It might also be useful to provide one set of images in the supplementary files.

· I recommend checking the manuscript for inconsistencies. For instance, FASTKD5 levels in FASTKD3&4-dKO (line 140) and FASTKD3-sKO cells (line 157). Interaction between FASTKD3 and FASTKD5 (line 159), but not in BioID data.

· It would help the reader to clarify that the BioID was performed in a polyploid cell line, which expresses FASTKD2, unlike the haploid cell line used throughout the manuscript. The reader might otherwise wonder how an interaction with in the FASTKD4-BirA BioID experiment was possible (Fig. S7).

· Clarification of the RNAseq data and polyadenylation experiment will benefit clarity of the results.

· In general, the manuscript could benefit from clarity and less speculation in the results section.

· It would help the reader if the canonical and non-canonical transcripts are defined and the transcript boarders described.

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: The manuscript describes the results of establishing cell lines in which the expression of one or two of the mitochondrial FASTKD proteins is knocked down. These proteins are involved in the RNA processing and post-transcriptional regulation of gene expression in the mitochondria. The work in this manuscript attempted looking and unraveling the function of each one of these family members in a comprehensive approach. The question of the control of gene expression of mitochondrial encoded genes is an important one and under an extensive study. Therefore, this manuscript would interest those who study mitochondrial gene expression, as well as those interested in RNA processing and stability. Although a defined clear picture of the mechanistic role of each member is still not at hand, this work is an important step towards this goal.

Major comments:

The authors use the terms “canonical” versus “non-canonical” transcripts throughout the manuscript. However, it is not clearly defined what is each one. Is a canonical transcript is the mature processed one or a transcript that is composed of the amino-acids coding region (and a polyA tail). For example, the matured processed CO1 has been mapped to have the tRNAS antisense serving as its 3’ UTR. Similarly, the mature ND6 transcript has been mapped to have a long 3’ UTR of about 450 nt (Slomovic et al MCB 2005). Therefore, all the mitochondrial transcripts should be precisely defined and described as to their 5’ and 3’ ends, even if they are surrounded by tRNAs. This is also applied for the polyadenylation sites (see below).

For example, the term pre-CO1 is used but no description of what exactly is that RNA molecule. The presented RACE results are of low resolution gel and the nt sequences of the RACE clones are not shown.

The same account to Fig 7 where the RNA molecules are schematically presented but the reader cannot identify the exact transcripts. These should be indicated using the mit genomic nt sequence numbering or a similar mapping system.

Fig 4 and S5 Fig. It is not clear what is presented here. Is the canonical mRNA region ends at the translational stop codon or at the mature 3’ end of the transcript? As said, these are not the same for several transcripts. Is the section of polyadenylation representing a polyA sequence or the 3’ UTR of the RNA / the seq 3’ to the CDS? This is not explained in the legends to figures and the ref indicated does not seems to be the right one. In addition, the title of Fig 4 seems to be not the right one and in the legend to S5 Fig it is indicated “reveals effects on polyadenylation in all mRNAs” which is not the case. For example, the last column in S5 Fig present the ND6 mRNA polyadenylation. This mature transcript is about 950 nt long and the polyadenylation is at the 3’ end. Only nt 445 to 525 sequence is presented here so where is the mature 3’ end?

Minor:

1. S3E Fig. The Bru and dsRNA staining is very faint and hard to detect.

2. What is the ND5-cytB junction? Define it clearly.

3. S4C Fig. The blot of the pre-CO1 is too faint.

4. Ref 64 does not seem the right one for the polyadenylation method.

Reviewer #2: Non canonical is given as “mitochondria, junctions not flanked by tRNA are found at the 3′ UTR of ND6, 5′ UTR of CO1, between ND5 and CYTB, and between ATP8/6 and CO3 mRNAs. “ This is a little misleading as some of these junctions do have tRNA like structures as they are derived from the antisense of the tRNA and are predicted to fold into a very similar structure. Thus the enzyme that facilitate the cleavage may be same as for junctions between ORFs and sense strand mt-tRNAs.

Fig 1 Although a number of probes have been shown at 2 exposure times, a number of the signals are overexposed (eg GRSF1, VDAC) and so any more subtle differences in levels are lost. The quality of some of the probe exposures is rather poor eg FASTKD3.

Fig 2 This is an extensive display of data but unfortunately not acceptable as essentially all of the signals are cut and paste of a single band. As a mosaic it is therefore impossible to know what was on the same blot, whether the loading was equal or represents the best from a composite of many individual blots. There are also no size markers to validate the identity of the signals.

The text states that “all the analyzed antisense or ncRNAs appeared as distinct bands with precise lengths”. There are no size markers provided so it is not possible to determine is the largest species is the correct length, non-specific larger species, unprocessed, or a discrete degradation product. This is particularly important considering in most of the antisense panels there are more than one species shown.

In this same section it states that “length of some ncRNAs is similar to the length of their complementary mRNAs,”. Without any size markers it is not really possible to make this conclusion.

It is therefore difficult to fully assess the validity of the data presented in this figure.

The lack of agreement, acknowledged by the authors, between the RNAseq and the northerns for some of the transcripts was a little concerning, as it makes it more difficult to have confidence in the remaining RNAseq data.

Fig 3B reflects a large amount of data. FASTKD5 KO in 3B is described as “ resulted in the accumulation of transcripts or junction containing RNAs that are antisense to the ND2, CO2, ATP8/6, CO3 and ND6 mRNAs,..”. If this refers to the red in the LSP derived trace, then it is not the whole RNA species that has elevated levels in a couple of the cases and an increase (red above the line) is not really evident for NT6. If this is not what is meant then the text is not clear to this reader.

Fig 4 – the term non-template adenylation is not used in the main text that uses polyadenylation. A degree of consistency in terminology would be helpful. The change in adenylation status is not clearly described or depicted in the figure. To the less knowledgeable reader the nucleotide position might be assumed to be the nucleotide position in the mtDNA whereas it reflects the length of the mature transcript. Considering the manuscript is about non-correctly processed it would be better to relate the nucleotide position to the mtDNA position. It would also be helpful to have an indicator of the correct end following processing as this will help to align where the polyadenylation might be expected to start. The change in colour to designate this is not made clear in the legend or the text. What is also not clear is what the drop off in the graph is meant to indicate. Does it mean that FASTKD3 KO MTCO2has a population of transcripts with shorter A tails ? Has this been validated by other means. If this is not what it signifies then it is not clear to this reader. This is particularly important when concluding that there was a difference in the FASTKD4 and FASTKD5 KOs, because this is difficult to see compared to traces for control and for the traces in the other graphs.

Minor points

Line 73 ‘span’ probably should be exchanged with ‘intersperse’ as span suggests coverage over the non-coding regions.

The lack of spacing between each transcript in Fig 3A makes it hard to take in the data. It is better presented in Fig 2.

Reviewer #3: The manuscript by Ohkubo and colleagues analyzed the consequences of deleting different FASTK genes in mitochondrial RNA processing and levels. Loss of FASTKD4 and FASTKD5 and their double knockout showed a strong respiratory phenotype, with decreases in CO1 and ND5. Comprehensive mitochondrial transcriptome analyses showed defects in processing at several canonical and non-canonical RNA junctions, accompanied by an increase in specific antisense transcripts. There was no effect on poly adenylation.

This comprehensive study allowed for a direct comparison between the FASTK forms and expanded our understanding of mitochondrial RNA processing mechanisms. I have relatively minor comments.

1- I was a bit confused with the cell line “with FASTKD3 and FASTKD4 genes were deleted also carried a mutation in one of the FASTKD5 alleles” HAP1 cells being haploid, the deletion of one FASTKD5 allele would be of consequence. Maybe I am missing something.

2- I was also confused with the western blots. FASTKD5 bands can still be observed in the single and double KOs. Please clarify.

3- The observation that “degradation. The fact that the length of some ncRNAs is similar to the length of their complementary mRNAs, which suggests that the RNA processing of the two strands may occur simultaneously” is difficult to judge, as the bands do not have MW markers and are in different panels.

4- If the translatability of ND5-CYTb transcript is correct, should we observe a decrease in cytochrome b protein? The gels shows an overlap with ND2, but please expand. The western blot on Figure 6 does show a decrease in UQCRC2, which may be due to lower cytochrome b.

5- The binding of FASTKD4 to tRNA E is indeed interesting, but it may just reflect the fact that it binds to the unprocessed transcript at that same sequence. Still, I agree that there should be preferential binding to the unprocessed.

**********

Have all data underlying the figures and results presented in the manuscript been provided?

Large-scale datasets should be made available via a public repository as described in the PLOS Genetics data availability policy, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer #1: Yes

Reviewer #2: No: Please see comment on Fig 2

Reviewer #3: Yes

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: Yes: Carlos T Moraes

Attachment

Submitted filename: The manuscript describes the results of establishing cell lines in which the expression of one or two of the mitochondrial FASKD proteins is knocked down.docx

Decision Letter 1

Gregory S Barsh, Christoph Freyer

28 Sep 2021

Dear Dr Ohkubo,

Thank you very much for submitting your Research Article entitled 'The FASTK family proteins fine-tune mitochondrial RNA processing' to PLOS Genetics.

The manuscript was evaluated by the original 2 peer reviewers. As you will see, reviewer 1 is positive but reviewer 2 remains concerned regarding Figure 2.

The manuscript and the reviews have now been discussed among members of the editorial board. Overall, we are positive about moving forward but ask that you make some additional changes to the presentation in a hopefully final round of minor revision. We recommend that, where possible, you provide images in figure 2 where WT and KO are loaded adjacent. You already provide this for FASTKD3-sKO, FASTKD4-sKO and you provided such an image to the reviewers (middle two lanes of Figure II in your response letter). Should you not have such configurations for the dKOs, please provide full images with WT and dKO on the same exposure as supplemental information (similar as you provided for reviewers only). All these images should be presented as supplemental data, as part of the revised manuscript. We also recommend to clearly state in the results and methods sections how the figure was composed and, if any, which lane contains a re-used WT control (i.e. it seems that the same WT blot is shown for FASTKD4-sKO and FASTKD3&4-dKO). Finally, we suggest that you clarify the polyA tail length in figure 4.

In addition we ask that you:

1) Provide a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

2) Upload a Striking Image with a corresponding caption to accompany your manuscript if one is available (either a new image or an existing one from within your manuscript). If this image is judged to be suitable, it may be featured on our website. Images should ideally be high resolution, eye-catching, single panel square images. For examples, please browse our archive. If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License. Note: we cannot publish copyrighted images.

We hope to receive your revised manuscript within the next 30 days. If you anticipate any delay in its return, we would ask you to let us know the expected resubmission date by email to plosgenetics@plos.org. If present, accompanying reviewer attachments should be included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our Submission Checklist.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Please be aware that our data availability policy requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as "data not shown" or "unpublished results" in manuscripts. All points should be backed up by data provided with the submission.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

PLOS has incorporated Similarity Check, powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, you will need to go to the link below and 'Revise Submission' in the 'Submissions Needing Revision' folder.

[LINK]

Please let us know if you have any questions while making these revisions.

Yours sincerely,

Christoph Freyer, PhD

Guest Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: The authors have answered the questions and changed the manuscript accordingly to the comments.

Reviewer #2: The authors have amended the publication mostly by eliminating text that was considered to be inappropriate by the reviewers.

Figure 2 is a crucial element of the manuscript containing data that is fundamental to the premise being presented. In response to comments about the fragmentary nature of Figure 2, there has been the addition of 2 sentences to state that the gel images in Fig 2 were pieces excised and from a single gel and re-assembled into a major figure. It also suggests that all the data were derived from a single gel/membrane. The example submitted to the editor/reviewers in the revision only shows FASTKD5 sKO suggesting that there were separate gels for each KO pairing, or where the same WT repeats used for each WT lane in Figure 2 ? The WT lanes would be expected to be identical, especially if the loading were equal and the same exposures retained, which they seem to be for the 5S. These do however differ between WT signals for many of the RNA species probed.

The additional figure for the reviewers is not at the same exposure/brightness as the manuscript version, so it is not completely possible to judge but is it the same pair of lanes used for each probe ? Since 5S and 7SL are given as loading controls and these appear to be reasonably equally loaded, why not use WT rep3 and FASTKD5 sKO rep1. That would allow these to be presented as a pair of signals in a single piece, as was done for FASTKD3 sKO and FASTKD4 sKO data, which would be marginally better than the original and current format, instead of 2 separate pieces.

WT NcND3 in fig 2 have no corresponding signal to that of the fastest mobility in the FASTKD5 sKO lane. This is different to the figure submitted to the reviewers as an example of the original gel, where the fast migrating doublet is visible in all 6 lanes.

This is not really acceptable quality for a journal such as PLOS Genetics. It is not evident that all of the sample were loaded on the same gel. The northern probings should be repeated with the samples loaded in the required order on a single gel that can be shown in its entirety.

These elements when taken together mean this figure is still below the quality this reviewer would expect of a PLOS Genetics manuscript.

Fig 4 seems to suggest that the poly(A) tail in WT controls is generally 15 nucleotides, which does not correspond with most of the literature including that cited by the authors in their response (Temperley et al 2010).

The comment about radioactive RNA markers is understood but RNA markers are available to run on the gels. Images of these on UV together with the 28S and 18S would allow for subsequent sizing to be shown.

**********

Have all data underlying the figures and results presented in the manuscript been provided?

Large-scale datasets should be made available via a public repository as described in the PLOS Genetics data availability policy, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer #1: Yes

Reviewer #2: Yes

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Gadi Schuster

Reviewer #2: No

Decision Letter 2

Gregory S Barsh, Christoph Freyer

11 Oct 2021

Dear Dr Ohkubo,

We are pleased to inform you that your manuscript entitled "The FASTK family proteins fine-tune mitochondrial RNA processing" has been editorially accepted for publication in PLOS Genetics. Congratulations!

Before your submission can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Please note: the accept date on your published article will reflect the date of this provisional acceptance, but your manuscript will not be scheduled for publication until the required changes have been made.

Once your paper is formally accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you’ve already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at plosgenetics@plos.org.

In the meantime, please log into Editorial Manager at https://www.editorialmanager.com/pgenetics/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production and billing process. Note that PLOS requires an ORCID iD for all corresponding authors. Therefore, please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field.  This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

If you have a press-related query, or would like to know about making your underlying data available (as you will be aware, this is required for publication), please see the end of this email. If your institution or institutions have a press office, please notify them about your upcoming article at this point, to enable them to help maximise its impact. Inform journal staff as soon as possible if you are preparing a press release for your article and need a publication date.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Genetics!

Yours sincerely,

Christoph Freyer, PhD

Guest Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

www.plosgenetics.org

Twitter: @PLOSGenetics

----------------------------------------------------

Comments from the reviewers (if applicable):

----------------------------------------------------

Data Deposition

If you have submitted a Research Article or Front Matter that has associated data that are not suitable for deposition in a subject-specific public repository (such as GenBank or ArrayExpress), one way to make that data available is to deposit it in the Dryad Digital Repository. As you may recall, we ask all authors to agree to make data available; this is one way to achieve that. A full list of recommended repositories can be found on our website.

The following link will take you to the Dryad record for your article, so you won't have to re‐enter its bibliographic information, and can upload your files directly: 

http://datadryad.org/submit?journalID=pgenetics&manu=PGENETICS-D-21-00596R2

More information about depositing data in Dryad is available at http://www.datadryad.org/depositing. If you experience any difficulties in submitting your data, please contact help@datadryad.org for support.

Additionally, please be aware that our data availability policy requires that all numerical data underlying display items are included with the submission, and you will need to provide this before we can formally accept your manuscript, if not already present.

----------------------------------------------------

Press Queries

If you or your institution will be preparing press materials for this manuscript, or if you need to know your paper's publication date for media purposes, please inform the journal staff as soon as possible so that your submission can be scheduled accordingly. Your manuscript will remain under a strict press embargo until the publication date and time. This means an early version of your manuscript will not be published ahead of your final version. PLOS Genetics may also choose to issue a press release for your article. If there's anything the journal should know or you'd like more information, please get in touch via plosgenetics@plos.org.

Acceptance letter

Gregory S Barsh, Christoph Freyer

3 Nov 2021

PGENETICS-D-21-00596R2

The FASTK family proteins fine-tune mitochondrial RNA processing

Dear Dr Ohkubo,

We are pleased to inform you that your manuscript entitled "The FASTK family proteins fine-tune mitochondrial RNA processing" has been formally accepted for publication in PLOS Genetics! Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out or your manuscript is a front-matter piece, the early version of your manuscript will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting PLOS Genetics and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Andrea Szabo

PLOS Genetics

On behalf of:

The PLOS Genetics Team

Carlyle House, Carlyle Road, Cambridge CB4 3DN | United Kingdom

plosgenetics@plos.org | +44 (0) 1223-442823

plosgenetics.org | Twitter: @PLOSGenetics

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Sequence analysis of the FASTKDs-KO genes in the HAP1 cell lines.

    Genomic modifications shown in (A) were detailed in (B).

    (TIF)

    S2 Fig. RNA-seq of the FASTKDs-KO genes in the HAP1 cell lines.

    Specific deletions in each of the targeted FASTKD genes in each of the HAP1 cell lines relative to the control HAP1 cell line were shown.

    (TIF)

    S3 Fig. Characterization of the FASTKDs-KO HAP1 cell lines.

    (A) Protein expression levels in 143B (control) and WT HAP1 cells were assessed by immunoblotting. Whole cell lysates (WCL) and mitochondria extracted from the cells were analyzed. mtHSP70 was used as a loading control. (B) mRNA expression levels in 143B (control) and WT HAP1 cells were analyzed by RT-PCR. (C) Relative abundance of 7S RNA in WT (control) and FASTKDs-KO HAP1 cells were quantified by RT-qPCR (n = 4). The amounts of 7S RNA were normalized by GAPDH. (D) The relative abundance of mtDNA in the FASTKDs-KO cells compared to controls was measured by qPCR and normalized to total nuclear DNA (n = 3). (E) WT and FASTKDs-KO HAP1 cells were labeled with BrU, MitoTracker Red, and DAPI, and immunolabeled with anti-SSBP1, anti-BrU and J2 anti-dsRNA. Immunofluorensce was analyzed by confocal microscopy. Scale bars indicate 20 μm. (F) The amount of mitochondrial dsRNA in the FASTKDs-KO cells and controls was measured by dot blotting. VDAC1 protein was used as a loading control. (G) Steady-state levels of mitochondrial tRNAs in WT (control) and FASTKDs-KO HAP1 cells were measured by northern blotting. 5S was analyzed as a loading control.

    (TIF)

    S4 Fig. The steady-state levels of rRNAs, mRNAs and ncRNAs in WT and FASTKDs-KO HAP1 cells measured by northern blotting.

    Related to Fig 2. Two entire gels/exposures are shown. 5S and 7SL were used as loading controls. Equal amounts of total cellular RNA were loaded on the gel. Independent biological samples were analyzed per genotype. The pair of WT #2 and FASTKD4-sKO (A), a pair of WT #2 and FASTKD3&4-dKO (A), a pair of WT #1 and FASTKD4&5-dKO (B), and a pair of WT #3 and FASTKD3-sKO (B) are also shown in Fig 2A.

    (TIF)

    S5 Fig. Rapid amplification of cDNA ends (RACE) and northern blotting of the 5′ UTR of the CO1 mRNA.

    (A) RACE of the 5′ UTR of CO1 mRNA in WT (control) and FASTKDs-KO HAP1 cells. (B) Sanger sequencing of the 5′ UTR of CO1 mRNA from WT HAP1 cells. (C) RACE of the 5′ end of CO2 mRNA in WT (control) and FASTKDs-KO HAP1 cells. (D) Northern blotting of RNA isolated from WT (control) and FASTKDs-KO HAP1 cells against the antisense tRNAY, CO1 mRNA, and 18S rRNA that was used as a loading control.

    (TIFF)

    S6 Fig. Polyadenylation status of mitochondrial mRNAs.

    Related to Fig 4. Mapping of RNA-seq reads to polyadenylated mitochondrial mRNA reference sequences was used to analyze the polyadenylation status of mRNAs in the FASTKDs-KO cell lines compared to controls. The canonical 3′ region of each mRNA is shown in dark grey and the section of polyadenosine is shown in light grey.

    (TIF)

    S7 Fig. FASTKD4 specifically binds to tRNAE.

    Related to Fig 5. (A-B) Strand specific HITS-CLIP read counts corresponding to the 13401–16569 region of the mtDNA for control (anti-HA antibody) (A) and anti-FASTKD4 antibody (B). (C) The tRNAE enriched through FASTKD4 immunoprecipitation from WT and FASTKD4-sKO HAP1 cells was quantified by strand-specific RT-qPCR. Anti-Flag antibody was used a s control. A representative result from two independent biological experiments is shown.

    (TIF)

    S8 Fig. BioID interactome analyses of FASTKD4 and FASTKD5.

    Log2FC (FASTKD4-BirA/control) (A) or Log2FC (FASTKD5-BirA/control) (B) was plotted against a sum of normalized total spectra. Only significantly enriched proteins are shown (Log2FC ≥ 1). Cells that do not express the bait protein were used as control. Mitochondrial proteins are shown in blue. Red dot represents BirA-tagged bait proteins. (C-D) Gene ontology analysis (GO—molecular function) of mitochondrial proteins identified by the BioID of FASTKD4 (C) and FASTKD5 (D). (E) Number of mitochondrial proteins found in either or both BioID data sets from FASTKD4 or FASTKD5.

    (TIF)

    S9 Fig. Function of the FASTK family proteins in the processing of tRNA-less junctions is evolutionarily conserved.

    (A) A schematic representation of fask-1 (B0564.7) deletion allele generated using CRISPR/Cas9 technology. Two sgRNAs each were used to cleave the genomic DNA near the start codon and in the last exon of the FASK-1 locus. The deletion allele fask-1(uge100) contains a truncated start codon, a 26 bp insertion and a 3642 bp deletion that removes all of the FASK-1 coding sequence except 153 bp of the last exon. (B) The steady-state levels of mitochondrial transcripts in WT (control) and FASK-1 deletion strains were measured by northern blotting. Act-1 was used as a loading control.

    (TIF)

    S1 Table. List of oligonucleotides used in this study.

    Sequences used for Gibson assembly are shown in bold. T7 promoter sequence is underlined.

    (TIF)

    Attachment

    Submitted filename: The manuscript describes the results of establishing cell lines in which the expression of one or two of the mitochondrial FASKD proteins is knocked down.docx

    Attachment

    Submitted filename: Response to reviewers.docx

    Attachment

    Submitted filename: Response to reviewers.docx

    Data Availability Statement

    RNA-seq datasets have been deposited in the NCBI GEO with accession numbers GSE156556 (HITS-CLIP) and GSE156260 (mitochondrial transcriptomics). The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD020993 and 10.6019/PXD020993. All other relevant data are within the manuscript and Supporting information.


    Articles from PLoS Genetics are provided here courtesy of PLOS

    RESOURCES